Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
Document #: FORM1 -000107830   Ed: 1.0 
Source Document #: SOP-000056619  Page 1 of 105 
Effective Date: See System Metadata    Confidential  Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453361] Name  [CONTACT_364034](s)  IND [ADDRESS_453362] : [ADDRESS_453363], Maidenhead, [LOCATION_006]  
Previous Version , if 
applicable  VERSION 2.0 
Date, if applicable  18 NOVEMBER 2021  
Property of  Seqirus*  
Confidential  
May not be used, divulged, published or otherwise disclosed without written consent of 
Seqirus  
*“Seqirus” includes all legal entities under which the company operates  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830   Ed: 1.0  
Source Document #: SOP-000056619   Page 2 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453364] of Abbreviations and Definition of Terms  ................................ ................................ .................  22 
1 BACKGROUND AND RATIO NALE  ................................ ................................ .....................  24 
1.1 Background ................................ ................................ ................................ ............................. 24 
1.2 Rationale  ................................ ................................ ................................ ................................ .26 
1.3 Potential Risks and Benefits  ................................ ................................ ................................ ...26 
2 STUDY OBJECTIVES ................................ ................................ ................................ .............  27 
2.1 Primary Objectives  ................................ ................................ ................................ ................. 27 
 Primary Immunogenicity Objectives  ................................ ................................ ................ 27 
2.2 Secondary Objectives  ................................ ................................ ................................ ............. 28 
 Secondary Immunogenicity Objective(s)  ................................ ................................ ......... 28 
 Secondary Safety Objective(s)  ................................ ................................ ......................... 29 
2.3 Exploratory Objectives  ................................ ................................ ................................ ........... 29 
3 STUDY DESIGN ................................ ................................ ................................ .......................  29 
3.1 Overview of Study Design  ................................ ................................ ................................ .....29 
3.2 Scientific Rationale for Study Design  ................................ ................................ .................... 31 
3.3 Justification for Dose  ................................ ................................ ................................ .............. 32 
3.4 Study Period  ................................ ................................ ................................ ........................... 32 
3.5 Blinding Procedures  ................................ ................................ ................................ ............... 32 
3.6 Data Collection  ................................ ................................ ................................ ....................... 33 
 Data Collected from Subjects  ................................ ................................ ........................... 33 
 Tools Used for Data Collection  ................................ ................................ ........................ 34 
3.7 Collection of Clinical Specimens  ................................ ................................ ........................... 35 
3.8 Stoppi[INVESTIGATOR_007]/Pausing Guidelines ................................ ................................ ................................ ..36 
3.9 Data Monitoring Committee ................................ ................................ ................................ ...36 
3.10  End of Study  ................................ ................................ ................................ ........................... 36 
4 SELECTIO N OF STUDY POPULATIO N ................................ ................................ .............  37 
4.1 Inclusion Criteria  ................................ ................................ ................................ .................... 37 
4.2 Exclusion Criteria  ................................ ................................ ................................ ................... 37 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830   Ed: 1.0  
Source Document #: SOP-000056619   Page 3 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
4.3 Criteria for Delay of Vaccination ................................ ................................ ............................ 39 
4.4 Criteria for Repeat Vaccination in the Study  ................................ ................................ .......... 40 
4.5 Premature Withdrawal from Study  ................................ ................................ ......................... 40 
5 STUDY PROCEDURES  ................................ ................................ ................................ ..........  42 
5.1 Prevac cination Procedures: Screening/Randomization  ................................ .......................... 42 
 Informed Consent  ................................ ................................ ................................ ............. 43 
 Screening  ................................ ................................ ................................ .......................... 43 
 Enroll ment  ................................ ................................ ................................ ........................ 45 
 Randomization  ................................ ................................ ................................ .................. 45 
 Blood Draw ................................ ................................ ................................ ....................... 46 
5.2 Vaccinat ion Clinic Visit  ................................ ................................ ................................ .......... 46 
5.3 Postvaccination Procedures  ................................ ................................ ................................ ....46 
 eDiary Reminder Alerts  ................................ ................................ ................................ ....48 
5.4 Postvaccination Visits  ................................ ................................ ................................ ............. 49 
 Follow -up Clinic Visit(s)  ................................ ................................ ................................ ..49 
 Safety Follow -up Calls  ................................ ................................ ................................ .....51 
5.5 Unscheduled Visits  ................................ ................................ ................................ ................. 52 
5.6 Study Completion/Termination Visit  ................................ ................................ ...................... [ADDRESS_453365] S ................................ ................................ ...............................  53 
6.1 Study Vaccine(s)  ................................ ................................ ................................ ..................... 53 
6.2 Non-Study Vaccines  ................................ ................................ ................................ ............... 57 
6.3 Vaccine Preparation and Administration  ................................ ................................ ................ 57 
6.4 Vaccine Administration Error or Overdose of Vaccine  ................................ .......................... 58 
6.5 Prior and Concomitant Medications and Vaccines  ................................ ................................ .58 
6.6 Vaccine Supply, Labeling, Storage and Tracking  ................................ ................................ ...60 
7 ASSESSMENTS  ................................ ................................ ................................ ........................  62 
7.1 Safety Assessments  ................................ ................................ ................................ ................. 62 
 Solicited Adverse Events  ................................ ................................ ................................ ..63 
 Unsolicited Adverse Events  ................................ ................................ .............................. 65 
 Evaluation of Adverse Events  ................................ ................................ ........................... 65 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830   Ed: 1.0  
Source Document #: SOP-000056619   Page 4 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
 Serious Adverse Events  ................................ ................................ ................................ ....67 
[IP_ADDRESS]  Adverse Events of Special Interest  ................................ ................................ ............. 68 
 Methods for Recording Adverse Events and Serious Adverse Events  ............................. 69 
[IP_ADDRESS]  Post-Study Events  ................................ ................................ ................................ .......70 
 Pregnancies  ................................ ................................ ................................ ....................... 70 
 Safety Laboratory Measurements  ................................ ................................ ..................... 70 
7.2 Efficacy Assessment  ................................ ................................ ................................ ............... 70 
7.3 Immunogenicity Assessment  ................................ ................................ ................................ ..70 
8 STATISTICAL CONSIDER ATIONS  ................................ ................................ .....................  71 
8.1 Endpoints  ................................ ................................ ................................ ................................ 71 
 Primary Endpoints  ................................ ................................ ................................ ............ 71 
[IP_ADDRESS] Primary Efficacy Endpoint(s)  ................................ ................................ ..................... 72 
[IP_ADDRESS]  Primary Immunogenicity Endpoint(s)  ................................ ................................ ........ 72 
[IP_ADDRESS]  Primary Safety Endpoint(s)  ................................ ................................ ........................ 73 
 Secondary Endpoint(s)  ................................ ................................ ................................ .....73 
[IP_ADDRESS]  Secondary Safety Endpoint(s)  ................................ ................................ .................... 73 
[IP_ADDRESS]  Secondary Efficacy Endpoint(s)  ................................ ................................ ................. 74 
[IP_ADDRESS]  Secondary Immunogenicity Endpoint(s)  ................................ ................................ ....74 
 Exploratory Endpoint(s)  ................................ ................................ ................................ ...75 
[IP_ADDRESS]  Exploratory Safety Endpoint(s)  ................................ ................................ .................. 75 
[IP_ADDRESS]  Exploratory Efficacy Endpoint(s) ................................ ................................ ............... 75 
[IP_ADDRESS]  Exploratory Immunogenicity Endpoint(s)  ................................ ................................ ..75 
8.2 Success Criteria  ................................ ................................ ................................ ...................... 75 
 Success Criteria for Primary Objective(s)  ................................ ................................ ........ 75 
[IP_ADDRESS]  Success Criteria for Primary Safety Objective(s)  ................................ ....................... 75 
[IP_ADDRESS]  Success Criteria for Primary Efficacy Obje ctive(s)  ................................ ................... 75 
[IP_ADDRESS]  Success Criteria for Primary Immunogenicity Objective(s)  ................................ ......76 
 Success Criteria for Secondary Objective(s)  ................................ ................................ ....76 
[IP_ADDRESS]  Success Criteria for Secondary S afety Objective(s)  ................................ ................... 76 
[IP_ADDRESS]  Success Criteria for Secondary Efficacy Objective(s)  ................................ ............... 76 
[IP_ADDRESS]  Success Criteria for Secondary Immunogenicity Objective(s)  ................................ ..76 
8.3 Analysis Sets  ................................ ................................ ................................ .......................... 77 
 All Enrolled Set  ................................ ................................ ................................ ................ 77 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830   Ed: 1.0  
Source Document #: SOP-000056619   Page 5 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
 All Exposed Set  ................................ ................................ ................................ ................ 77 
 Safety Set  ................................ ................................ ................................ .......................... 77 
 Full Analysis Set (FAS) Immunogenicity  ................................ ................................ ......... 77 
 Per Protocol Set (PPS) Immunogenicity  ................................ ................................ .......... 78 
 Other Analysis Set(s)  ................................ ................................ ................................ ........ 78 
 Subgroup(s)  ................................ ................................ ................................ ...................... 78 
 Protocol Deviation(s)  ................................ ................................ ................................ ........ 79 
8.4 Statistical Analysis Plan  ................................ ................................ ................................ ......... 79 
 Analysis of Demographic and Baseline Characteristics  ................................ ................... 79 
 Analysis of Primary Objective(s)  ................................ ................................ ..................... 79 
[IP_ADDRESS]  Analysis of Primary Safety Objective(s)  ................................ ................................ ....79 
[IP_ADDRESS]  Analysis of Primary Efficacy Objective(s)  ................................ ................................ .79 
[IP_ADDRESS]  Analysis of Primary Immunogenicity Objective(s)  ................................ .................... 79 
[IP_ADDRESS].1  Statistical Hypothesis  ................................ ................................ ........................... 80 
[IP_ADDRESS].2  Analysis Sets  ................................ ................................ ................................ ........ 81 
[IP_ADDRESS].3  Statistical Methods  ................................ ................................ ............................... 82 
 Analysis of Secondary Objective(s)  ................................ ................................ ................. 83 
[IP_ADDRESS]  Analysis of Secondary Safety Objective(s)  ................................ ................................ 83 
[IP_ADDRESS].1  Analysis of Extent of Exposure  ................................ ................................ ............ 83 
[IP_ADDRESS].2  Analysis of Solicited Local, Systemic and Other Adverse Events  ....................... 83 
[IP_ADDRESS].3  Analysis of Unsolicited Adverse Events  ................................ .............................. 84 
[IP_ADDRESS].4  Statistical Hypotheses  ................................ ................................ ........................... 85 
[IP_ADDRESS].5  Analysis Sets  ................................ ................................ ................................ ........ 85 
[IP_ADDRESS].6  Statistical Methods  ................................ ................................ ............................... 85 
[IP_ADDRESS]  Analysis of Secondary Efficacy Objective(s) ................................ ............................. 85 
[IP_ADDRESS].1  Statistical Hypotheses  ................................ ................................ ........................... 85 
[IP_ADDRESS].2  Analysis Sets  ................................ ................................ ................................ ........ 85 
[IP_ADDRESS].3  Statistical Methods  ................................ ................................ ............................... 85 
[IP_ADDRESS]  Analysis of Secondary Immunogenicity Objective(s)  ................................ ................ 85 
[IP_ADDRESS].1  Statistical Hypotheses  ................................ ................................ ........................... 85 
[IP_ADDRESS].2  Analysis Sets  ................................ ................................ ................................ ........ 86 
[IP_ADDRESS].3  Statistical Methods  ................................ ................................ ............................... 86 
 Analysis of Other Objective(s)  ................................ ................................ ......................... 87 
[IP_ADDRESS]  Analysis of Other Safety Objective(s)  ................................ ................................ ........ 87 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830   Ed: 1.0  
Source Document #: SOP-000056619   Page 6 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
[IP_ADDRESS]  Analysis of Other Efficacy Objective(s)  ................................ ................................ ....87 
[IP_ADDRESS]  Analysis of Other Immunogenicity Objective(s)  ................................ ....................... [ADDRESS_453366] RETENTION  ................................ ................................ ................................ ..........  92 
12 USE OF INFORMATION A ND PUBLICATION  ................................ ................................ . 93 
13 ETHICAL CONSIDERATIO NS ................................ ................................ .............................  93 
13.1  Regulatory and Ethical Compliance  ................................ ................................ ....................... 93 
13.2  Informed Consent Procedures  ................................ ................................ ................................ 94 
13.3  Responsibilities of the Investigator and IRB/EC ................................ ................................ ....[ADDRESS_453367]  ................................ ................................ ................................ .................  96 
APPENDIX 1 – PREDICTION RULE ................................ ................................ ...........................  100 
APPENDIX 2 – LIST OF ADVERSE EVENTS OF SPECIAL INTEREST  ................................ . 101 
APPENDIX 3 – SPONSOR AND INVESTIGATOR SIGNATURE [CONTACT_118585]  ................................  104 
  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830   Ed: 1.0  
Source Document #: SOP-000056619   Page 7 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453368] of Tables  
Table 0 -1: Time and Events Schedule  ................................ ................................ ...............................  19 
Table 5 -1: Study Procedures  ................................ ................................ ................................ .............  42 
Table 6 -1: aQIV Vaccine (Fluad Tetra/Quadrivalen t) Composition  ................................ .................  55 
Table 6 -2:  Composition  ................................ ................................ .........  56 
Table 7 -1: Severity Grading for Solicited Systemic Adverse Events  ................................ ...............  64 
 
  

 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830   Ed: 1.0  
Source Document #: SOP-000056619   Page 8 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
 PROTOCOL SYNOPSIS  V118_23  
Name [CONTACT_790]:  
Seqirus [LOCATION_006] Limited  Protocol number:  
V118_23  Generic name [CONTACT_29323](s):  
MF59 -adjuvanted Quadrivalent Subunit 
Inactivated Influenza Vaccine (aQIV)  
Licensed comparator: nonadjuvanted 
Quadrivalent  Influenza Vaccine (QIV)  
Title of Study:  
A Phase 3, Randomized, Observed -blind, Controlled, Multicenter, Clinical Study to 
Evaluate Immunogenicity and Safety of an MF59 -adjuvanted Quadrivalent Subunit 
Inactivated Influenza Vaccine in Comparison with a Li censed Quadrivalent Influenza 
Vaccine, in Adults 50 to 64 Years of Age  
Study Period:  Approximately 9 months 
for each study participant.  Clinical Phase : 3 
Background and Rationale: Influenza is an infectious disease caused by [CONTACT_29226], an orthomyxovirus with two clinically relevant types (types A and B). The disease 
is characterized  by [CONTACT_29227][INVESTIGATOR_19256], such as 
fever, myalgia, headache,  severe malaise, nonproductive cough, sore throat, and rhinitis, 
and occurs in epi[INVESTIGATOR_363921].  
It has been recognized  for many years that people 65 years of age and older are at  
greater risk of serious complications from influenza  compared with young, healthy 
adults because human immune defences  become weaker with age. However, there is 
also a growing recognition of a high burden of disease in adults 50 -64 years  of age . 
About one -fifth of the [LOCATION_002] ( US) population (approximately 63 million people) 
is between [ADDRESS_453369] an underlying medical condition that puts them at higher risk for influenza 
complicat ions ( CDC 2019 ). Therefore, vaccination in this age group can offer 
significant reduction in the burden of influenza. In the US, the estimated rate of 
hospi[INVESTIGATOR_363922] 3-fold higher in adults 50-64 year s of age 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830   Ed: 1.0  
Source Document #: SOP-000056619   Page 9 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
Name [CONTACT_790]:  
Seqirus [LOCATION_006] Limited  Protocol number:  
V118_23  Generic name [CONTACT_29323](s):  
MF59 -adjuvanted Quadrivalent Subunit 
Inactivated Influenza Vaccine (aQIV)  
Licensed comparator: nonadjuvanted 
Quadrivalent  Influenza Vaccine (QIV)  
compared to the younger  adult (18 -49 years) age group ( 155.1  vs 48.4 per 100,000). 
Furthermore, the estimated number  of medical visits due to influenza illnesses is even 
higher in the 50  to 64 year s age group (3. 97 million) compared to a dults  65 years of age 
and older  (1.72 million) (CDC 2018 -2019 ). While the effect of influenza vaccination on 
the high  rates of  mortality and hospi[INVESTIGATOR_363923] 65 years and old er, these issues remain an unmet medical need for adults as 
young as 50 years.   
In 2010, the Advisory Committee on Immunization Practices ( ACIP ) acknowledged a 
high burden of influenza disease in individuals 50 to 64 years of age and , as a 
consequence , defined the risk group for older adults as 50 years  and older . In the United 
Kingdom  ([LOCATION_006]) , the 2020/2021 national influenza  vaccination program was extended to 
include adults 50 -64 of age ( NHS 2020 ). In addition, several  national government 
public health agencies (Austria, [LOCATION_013], Hungary, and Russia) issued 
recommendations for vaccination of all individuals of 60 years of age and above instead 
of ≥65 years of age  (Lang et al. 2012 ). 
Vaccination is considered the best approach to lower the burden of influenza disease. 
The efficacy in older individuals is significantly lower due to the aging of the immune  
system (i.e. immunosenescence) and underlying medical conditions that can both  
increase the risk of influenza complications as well as interfere with immune responses  
(Sasaki et al. 2011 ). Relatively low efficacy of conventional influenza vaccines in older  
adults provides an opportunity for vaccine improvement by [CONTACT_363945].  Older individuals have fewer naive B and T cells, more memory 
cells, and an increasing  number of senescent cells which are known to exert a regulatory 
role in vivo (Lang et al. 2012 ). Assuming the immune response becomes gradually 
weaker with age, and immune cells require  a stronger stimulus, novel vaccine 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830   Ed: 1.0  
Source Document #: SOP-000056619   Page 10 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
Name [CONTACT_790]:  
Seqirus [LOCATION_006] Limited  Protocol number:  
V118_23  Generic name [CONTACT_29323](s):  
MF59 -adjuvanted Quadrivalent Subunit 
Inactivated Influenza Vaccine (aQIV)  
Licensed comparator: nonadjuvanted 
Quadrivalent  Influenza Vaccine (QIV)  
formulations are needed to elicit an effective vaccination -mediated immunity in older 
individuals ( Aiello et al . 2019 ). 
One way to increase the immunogenicity  of influenza vaccines is by  [CONTACT_363946], 
such as the squalene and water emulsion adjuvant, MF59. Fluad®, Seqirus’ trivalent 
seasonal influenza vaccine adjuvanted with MF59 ( aTIV), is licensed for use in persons 
65 years of age and above in Europe since 1997 and in the US since 2015. More 
recently, t he quadrivalent version of Fluad (aQIV including A/H1N1, A/H3N2, 
B/Yamagata and B/Victoria strains) is licensed in Australia (since 24 Sep 2019), the US 
(since 21 Feb 2020), in the European Union (EU) including Iceland, Norway and 
Liechtenstein (since 26 May 2020), New Zealand (since Dec 2020), and in the [LOCATION_006] for 
use in adults aged 65 years and older. In multiple clinical studies, Fluad induced a 
significantly  higher immune response compared to conventional nonadjuvanted 
influenza vaccines  in subjects aged 65 years and older, including those with 
comorbidities  (Frey et al . 2014 ). 
The results of clinical studies conducted with Fluad (aTIV)  in healthy individuals 50 -64 
years and subjects 18 -60 years of age with chronic medical conditions, demonstrated 
similar benefits  as has been seen in adults 65 y ears of age and older  in terms of 
immunogenicity  (Baldo  et al. 2007 ; O’Hagan  et al. 2011 ; Noh et al. 2016). Similar to  
the findings in older adults , an acceptable safety and tolerability profile was seen in 
adults under [ADDRESS_453370] for more than 6 months. Persistence of vaccine -induced 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830   Ed: 1.0  
Source Document #: SOP-000056619   Page 11 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
Name [CONTACT_790]:  
Seqirus [LOCATION_006] Limited  Protocol number:  
V118_23  Generic name [CONTACT_29323](s):  
MF59 -adjuvanted Quadrivalent Subunit 
Inactivated Influenza Vaccine (aQIV)  
Licensed comparator: nonadjuvanted 
Quadrivalent  Influenza Vaccine (QIV)  
immunity over periods longer than a typi[INVESTIGATOR_363924].  
The aim of this study is to demonstrate both a noninferior immune response with 
regards to geometric mean titer ( GMT ) ratio and seroconversion rate ( SCR ) difference 
for each strain and a superior immune response with regards to GMT ratio for at least 2 
of the 4 strains of aQIV compared with  a licensed nonadjuvanted quadrivalent influenza 
vaccine , 3 weeks after vaccination in adults 50 -64 years of age . In addition,  
immunogenicity, antibody persistence , reactogenicity and safety  will be assessed.  Data 
from this study will be used to expand  the lice nsure of the quadrivalent version of Fluad  
for the prevention of seasonal influenza in adults 50 -64 years of age.  
Disclosure Statement : This is a randomized immunogenicity study with 2 arms that is 
observer -blinded.  
Study Objectives:   
Primary Immunogenicity Objective(s):  
1a. To demonstrate immunological noninferiority of aQIV versus a nonadjuvanted  
quadrivalent influenza vaccine  comparator ( QIV) in subjects 50 -64 years of 
age, as measured by [CONTACT_35318] (HI)1 geometric mean tite rs 
(GMTs) and seroconversion rates (SCR s) for each vaccine strain, at 3 weeks 
after vaccination.  
                                                 
1 In case of lack of agglutination or agglutination mediated through neuraminidase for a specific strain using HI assay, 
immunogenicity for that strain will be assessed as measured by [CONTACT_363947] (MN) assay as an acceptable alternative.  
 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830   Ed: 1.0  
Source Document #: SOP-000056619   Page 12 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
Success criteria:  
Noninferiority will be demonstrated if the upper limit ( UL) of the 95% 
confidence interval ( CI) for the inter-group GMT ratio2 (QIV/aQIV) is ≤1.5 
for each vaccine strain, and the UL of the 95% CI for the difference in SCR3 
(QIV-aQIV) is ≤10% for each vaccine strain.  
1b. To demonstrate that aQIV induces a superior immune response compared with 
QIV in subjects [ADDRESS_453371] 2 of the 4 vaccine strain s. 
Success criteria:  
Superior immune response will be demonstrated if the UL of the 95% CI for 
the inter-group GMT ratio ( QIV/aQIV) is <1.[ADDRESS_453372] 2 of the 4 vaccine 
strain s. 
Secondary Immunogenicity Objective:   
2a. To demonstrate that aQIV induces a superior immune response compared with 
QIV in subjects [ADDRESS_453373] one  
vaccine strain at 3 weeks after vaccination.  
Success criteria:  
Superior immune response will be demonstrated if the UL of the 98.73% CI 
for the inter-group GMT ratio (QIV/aQIV)  is <0.[ADDRESS_453374] one 
vaccine strain  at 6 months after vaccination with aQIV compared with  QIV as 
measured by [CONTACT_132370]1 in subjects 50 -64 years of age.  
Success criteria:  
Greater persistence of the immune response will be demonstrated if the UL of 
the 98.73% CI for inter -group GMT ratio ( QIV/aQIV ) <1.0 for one or more 
vaccine strain s. 
2c. To evaluate the immunogenicity of aQIV compared with QIV as measured by 
[CONTACT_132370]1 in subjects 50 -64 years of age.  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830   Ed: 1.0  
Source Document #: SOP-000056619   Page 13 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
Name [CONTACT_790]:  
Seqirus [LOCATION_006] Limited  Protocol number:  
V118_23  Generic name [CONTACT_29323](s):  
MF59 -adjuvanted Quadrivalent Subunit 
Inactivated Influenza Vaccine (aQIV)  
Licensed comparator: nonadjuvanted 
Quadrivalent  Influenza Vaccine (QIV)  
Exploratory  Immunogencity Objective s: 
- To evaluate  persistence of the immune response at 9 months after 
vaccination with aQIV compared with QIV as measured by [CONTACT_132370] 1 in subjects 
50-64 years of age.  
- To further evaluate the immunogenicity of aQIV compared with QIV in 
subjects 50 -64 years of age, with alternative assays, if sera permit.  
Secondary Safety Objective:  
To assess the safety and reactogenicity of aQIV and QIV in adults 50 -64 years.  
Primary and Secondary Immunogenicity Endpoint(s):  
A detailed description of primary and secondary endpoints is provided  in Section 8.1, 
Endpoints . 
Study Design:  
Experimental design: This is a Phase 3, randomized, comparator -controlled, observer -
blind, multicenter study in approximately 2,018 adults 50  to ≤64 years of age.  
                                                 
2 The GMT ratio is defined as the geometric mean of the postvaccination HI titer for QIV over the geometric mean of 
postvaccination HI titer for aQIV.  
3 The SCR is defined  as the percentage of subjects with either a prevaccination HI titer <1:10 and a postvaccination HI titer ≥1:40 or 
a prevaccination HI titer ≥1:10 and a ≥4 -fold increase in postvaccination HI titer. Difference in SCR is defined as SCR QIV ─ 
SCR aQIV. 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830   Ed: 1.0  
Source Document #: SOP-000056619   Page 14 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
Name [CONTACT_790]:  
Seqirus [LOCATION_006] Limited  Protocol number:  
V118_23  Generic name [CONTACT_29323](s):  
MF59 -adjuvanted Quadrivalent Subunit 
Inactivated Influenza Vaccine (aQIV)  
Licensed comparator: nonadjuvanted 
Quadrivalent  Influenza Vaccine (QIV)  
Duration of the study:  The study duration is approximately [ADDRESS_453375].  
Vaccination schedule:  single vaccination (Day 1).  
Study vaccine:  aQIV vaccine.  
Comparator vaccine : nonadjuvanted QIV .  
Treatment  groups:  
aQIV group: approximately 1,009 subjects receiving one dose of aQIV at Day 1.  
QIV group: approximately 1,009 subjects receiving one dose of QIV at Day 1.  
Randomization:  an Interactive Response Technology (IRT) will be used in the study  
with stratification factors for age (50 -59 and 60 -64 years of age) and history of any 
influenza vaccination within the previous  3 influenza seasons (yes/no). Subjects will be 
enrolled and stratified equally into two age groups (50 -59 years and 60 -64 years) with 
approximately 50 % of  subjects per age group  and w ithin each age group subjects will be 
randomized to the aQIV or QIV group according to a 1:1 ratio.  Stratification for history 
of any  influenza vaccination within  the previous  3 influenza seasons (yes/no) will be 
applied to all subjects . 
Blinding:  Observer -blind study.  
Blood sample schedule:  Four blood samples (approximately 10 mL each) will be 
collected from all subjects on Days 1, 22,  181, and 271.  
Data collection:  electronic Diary (eDiary), electronic Case Reporting Form (eCRF).  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830   Ed: 1.0  
Source Document #: SOP-000056619   Page 15 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
Name [CONTACT_790]:  
Seqirus [LOCATION_006] Limited  Protocol number:  
V118_23  Generic name [CONTACT_29323](s):  
MF59 -adjuvanted Quadrivalent Subunit 
Inactivated Influenza Vaccine (aQIV)  
Licensed comparator: nonadjuvanted 
Quadrivalent  Influenza Vaccine (QIV)  
Study clinic visits:  Four clinic visits for each subject at Days 1, 22, 181 , and 271.  
Safety phone call : Two safety phone calls (Day 15 and Day 91) will be conducted : on 
Day [ADDRESS_453376] any unsolicited adverse events ( AEs), including medications 
associated with these events  and any vaccinations , and on Day [ADDRESS_453377] only serious 
AEs ( SAEs ), AEs leading to withdrawal, and AEs of special interest (AESIs), and 
associated concomitant medications  and any vaccinations . 
Solicited AEs  occurring on the day of study vaccination through  the following 6 days 
(Day 1 through Day 7, or longer if the events  are not resolved),  will be recorded daily 
using an eDiary as completed by [CONTACT_423] . 
Safety data collection:  All u nsolicited AEs  occurring within 21 days (Day 22) after 
study vaccination will be collected. During the follow -up period (Day s 23- 271) only 
SAEs, AEs leading to withdrawal, and AESIs  will be collected. These data will be 
captured by [CONTACT_363948]. Subjects will be instructed to call the site in the 
event of any AE which they perceive as being of concern during the entire study period.  
Serological assays :  
HI1 assay for homologous vaccine strains, usin g egg-derived  target virus, will be 
performed for all subjects on serum samples collected on Days 1, 22, 181 , and 271.  
Written informed consent  will be obtained before conducting any study -specific 
procedures.  
Number of Subjects planned:  Approximately 2,018 subjects are planned to  be enrolled 
into this study, randomized 1:1 to aQIV or QIV. 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830   Ed: 1.0  
Source Document #: SOP-000056619   Page 16 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
Name [CONTACT_790]:  
Seqirus [LOCATION_006] Limited  Protocol number:  
V118_23  Generic name [CONTACT_29323](s):  
MF59 -adjuvanted Quadrivalent Subunit 
Inactivated Influenza Vaccine (aQIV)  
Licensed comparator: nonadjuvanted 
Quadrivalent  Influenza Vaccine (QIV)  
Study Population and Subject Characteristics:  The list of inclusion and exclusion 
criteria is included in  Sectio n 4, Selection of Study Population . 
Study Procedures:  
Written informed consent must be obtained prior to any study -related procedures. The 
informed consent process may be conducted up to 10 days before the day of vaccination 
(Day 1).  
After informed consent is signed by [CONTACT_423], prior to vaccination o n Day 1, 
screening evaluations will be performed including an eligibility assessment, a review of  
relevant medical history, physical examination, and height and weight measurements. 
Once all eligibili ty assessments are completed and subject is confirmed as eligible, a  
blood sample will be collected from all subjects for influenza -specific serology testing. 
Subjects will be assessed for risk of complications from influenza using the 
standardized scoring  system  (Hak et al . 2004 ). 
All eligible subjects will then be randomized and subsequently receive a single dose of 
0.5 mL of study vaccine to which they were assigned.  Blood samples for serology 
testing will be  collected on Day 1 (prior to  vaccination), Day 2 2, Day 181  and Day 271. 
Subjects will be followed  up for safety for 270 days after vaccination  (approximately 9 
months) . 
Further details on the study procedures are presented at the end of the synopsis  Table 
0-1 and in Section 5, Study Procedures . 
Study Vaccines:  Regardless of the type of a vaccine assigned in the trial, subjects will 
receive a 0.5 mL dose.  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830   Ed: 1.0  
Source Document #: SOP-000056619   Page 17 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
Name [CONTACT_790]:  
Seqirus [LOCATION_006] Limited  Protocol number:  
V118_23  Generic name [CONTACT_29323](s):  
MF59 -adjuvanted Quadrivalent Subunit 
Inactivated Influenza Vaccine (aQIV)  
Licensed comparator: nonadjuvanted 
Quadrivalent  Influenza Vaccine (QIV)  
Adjuv anted Quadrivalent Influenza Vaccine ( aQIV, investigational vaccine ) 
An adjuvanted inactivated subunit quadrivalent influenza vaccine, administered as one 
0.5 mL intramuscular dose into the deltoid muscle. The vaccine is presented in a pre -
filled needleles s syringe  (PFS) . Each 0.5 mL dose contains 15 μg hemagglutinin (HA) 
from each of the four influenza strains recommended by [CONTACT_363949] 2021/ 2022 Northern Hemisphere influenza season for quadrivalent vaccines.  
Licensed Comparator : nonadjuvanted Quadrivalent Influenza  Vaccine   
A nonadjuvanted inactivated quadrivalent influenza vaccine administered as one 0.5 mL 
intramuscularly into the deltoid muscle. The vaccine is presented in a pre -filled 
needleless syringe (PFS) . Each 0.5 mL dose  contains 15 μg HA from each of the four 
influenza strains recommended by [CONTACT_363950] 2021/ 2022 
Northern Hemisphere influenza season for quadrivalent vaccines.  
Statistical Analyses:  
The primary analysis will be conducted on the i mmunogenicity data collected up to 
Day 22. 
Sample Size Estimation:  
With 1:1 randomization, a  sample size of 1,816 evaluable subjects is chosen so that with 
one-sided alpha=0.025, there will be at least 90% power to achieve the primary 
objectives (1a and 1b). Assuming 10% drop out, the total sample size for the study is 
2,018  subjects . 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830   Ed: 1.0  
Source Document #: SOP-000056619   Page 18 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
Name [CONTACT_790]:  
Seqirus [LOCATION_006] Limited  Protocol number:  
V118_23  Generic name [CONTACT_29323](s):  
MF59 -adjuvanted Quadrivalent Subunit 
Inactivated Influenza Vaccine (aQIV)  
Licensed comparator: nonadjuvanted 
Quadrivalent  Influenza Vaccine (QIV)  
More details on the sample size calculation are provi ded in Section 8.5, Sample Size 
and Power Considerations of Primary Objectives . 
aQIV will be tested against a licensed nonadjuvanted quadrivalent influenza vaccine 
(QIV). This study is powered to demonstrate the GMT superiority of aQIV vs QIV 
assessed by  [CONTACT_363951] -primary endpoints associated with primary objective 1b) at 
significance level of one -sided α=0.025.  
Hypothesis testing will be carried out by 1a) and 1b) sequentially. Only after the NI 
objectives are achieved , the superiority objectives will be tested. All tests are carried out 
with a one -sided alpha of 0.025 for each comparison. No adjustment for multiple 
endpoints for the primary objective s is necessary .  
The Per Protocol Set (PPS) will be used for the noninferiority  analyses, and the Full 
Analysis Set (FAS) will be used for superiority analyses.  
Details on the statistical analysis can be found  in Section 8, Statistical Considerations . 
Interim Analysis:  An interim analysis is not planned for this study.  
Data Monitoring Committee : An independent Data Monitoring Committee will not be 
utilized for the study.  
 
 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619   Page 19 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
Schema  
Table 0-1: Time and Events Schedule  
 Visit Type  Clinic Visit  Safety Phone 
Call Clinic Visit * Safety Phone 
Call Clinic Visit * Clinic Visit * 
 Study Day  1 15 22 91 181 271 
 Visit Window 
(Days)  n/a -3 to +3 -3 to +7 -7 to +7 -14 to +14  -14 to +14  
 Visit Number  1 2 3 4 5 6 
Study Event  References       
Study Treatment        
Vaccination  Section 5.2  X      
Screening and Safety         
Informed Consenta Section 5.1.1  X      
Demographics and baseline 
characteristics  Section 5.1.2  X      
Medical Historyb Section 5.1.2  X      
Physical Examc Section 5.1.2  X  X  X X 
Pregnancy Testd Section 5.1.2  X      
Exclusion/Inclusion Criteria  Section [ADDRESS_453378] eDiary Dispensed 
with Training  Section 5.3  X      
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619   Page 20 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
 Visit Type  Clinic Visit  Safety Phone 
Call Clinic Visit * Safety Phone 
Call Clinic Visit * Clinic Visit * 
 Study Day  1 15 22 91 181 271 
 Visit Window 
(Days)  n/a -3 to +3 -3 to +7 -7 to +7 -14 to +14  -14 to +14  
 Visit Number  1 2 3 4 5 6 
Study Event  References       
Review of eDiary data and  
compliance  Section 3.6.2  Ongoing during eDiary use     
Assess all AEs  Section 7.1.2  X X X    
Assess SAEs  Section 7.1.4  X X X X X X 
Assess for AEs leading to 
withdrawal, and AESIs  Section [IP_ADDRESS]  X X X X X X 
Assess relevant medications  
and vaccinations  Section 6.5  X X X X X X 
Immunogenicity         
Serology blood drawe Section 5.1.5  Xf  X  X X 
Study Completion Procedure        
Study Completion/ Early 
Terminationg Section 5.6       X 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619   Page 21 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
 Visit Type  Clinic Visit  Safety Phone 
Call Clinic Visit * Safety Phone 
Call Clinic Visit * Clinic Visit * 
 Study Day  1 15 22 91 181 271 
 Visit Window 
(Days)  n/a -3 to +3 -3 to +7 -7 to +7 -14 to +14  -14 to +14  
 Visit Number  1 2 3 4 5 6 
Study Event  References       
Notes: * In the exceptional case that a clinic visit is not possible,  and if in line with country and site regulations  with appropriate sponsor approvals , a 
home visit may be con ducted . 
a Consent form should be signed prior to performing any study procedures. The informed consent process may be conducted earlier, but within  10 days 
prior to Day 1 ; 
b Medical history includes existing comorbidities ; 
c A physical examination will be based on a review of systems, i .e., a structured interview for complaints for each organ system;  
d A pregnancy test should be done for females of childbearing potential ; 
e Subjects at selected sites may be asked to voluntarily provide extra blood samples of 50 mL at Day 1 and Day 22  (see Section 3.7, Collection of 
Clinical Specimens ); 
f Blood sample for ser ology to be taken after temperature measurement, but prior to vaccination;  
g Subjects who terminate the study early will be requested to complete all safety -related Study Completion procedures.  
 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 22 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453379] Research Organization  
CSR   Clinical Study Report  
CTAB   cetyltrimethylammonium bromide  
DMC   Data Monitoring Committee  
EC  Ethics Committee  
EDC   electronic data capture  
eCRF   electronic Case Report Form  
EMA   European Medicines Agency  
FAS  Full Analysis Set  
FDA   [LOCATION_002] Food and Drug Administration  
GCP   Good Clinical Practice  
GDPR   General Data Protection Regulation  
GMFI  geomet ric mean fold increase  
GMT   geometric mean titer  
GMTr   geometric mean titer ratio  
HA  hemagglutinin  
HI  hemagglutination inhibition  
ICH The International Council for Harmonization of Technical Requirements for 
Pharmaceuticals for Human Use  
IB  Investigator’s Brochure  
ICF  informed consent form  
ID  identification  
IRB  Institutional Review Board  
IRT  Interactive Response Technology  
MF59   MF59C.1 adjuvant  
NH  Northern Hemisphere  
PFS  pre-filled syringe  
PPS  Per Protocol Set  
PVRM   Pharmacovigilance and Risk Management  
QIV  Quadrivalent Influenza Vaccine  
SAE   serious adverse event 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 23 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453380] Operating Procedure  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reaction  
TIV  Trivalent Influenza Vaccine  
UL  upper limit 
[LOCATION_006]  [LOCATION_008]  
US  [LOCATION_002]  
WHO   World Health Organization  
 
Abbreviation  or Term  Definition  
Follow -up period  The follow -up period for subjects starts at Day 23  and 
continues up to the study completion visit, defined as 9 months  
after vaccination  (Day 23 – Day 271 , i.e. end of study) . 
Qualified healthcare 
professional  Any licensed  healthcare professional who is permitted by 
[CONTACT_363952]  (as applicable to the protocol) , is trained on the 
study procedure(s) and who is identified within the site 
signature [CONTACT_77288].  
Trained healthcare 
professional  Any healthcare professional who is permitted by [CONTACT_274424], trained to perform delegated tasks, is trained on the 
study procedure(s) and who is identified within the site 
signature [CONTACT_77288].  
Treatment per iod Per protocol treatment period begins at the time of vaccination 
and ends 2 1 days after vaccination  (Days 1 -22). 
 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 24 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
1 BACKGROUND AND RATIO NALE  
1.1 Background  
Influenza is an infectious disease caused by [CONTACT_29239], an orthomyxovirus with two 
clinically relevant types (types A and B). The disease is characterized by [CONTACT_363953][INVESTIGATOR_19256], such as fever, myalgia, headache,  severe malaise, 
nonproductive cough, sore throat, and rhinitis  (Temte et al. 2010 ) and occurs in epi[INVESTIGATOR_363925]. In 
general, influenz a is resolved  within 2 to 7 days , although the symptoms cough and malaise may be 
prolonged. However,  influenza can exacerbate underlying medical conditions and/or lead to 
secondary viral or bacterial  pneumonia for some people, notably older adults and thos e with 
chronic diseases ( including  pulmonary or circulatory disorders, metabolic disorders such as 
diabetes mellitus, renal  dysfunction, or immunosuppression) ( Rothberg et al. 2008 ; Fiore et al. 
2009 ). 
It has been recognized for many years that people 65 years and older are at greater risk of serious 
complications from influenza compared with young, healthy adults because human immune 
defenses  become weaker with age. However, there is als o a growing recognition of a high burden of 
disease in adults 50 -64 years  of age . About one -fifth of the [LOCATION_002] ( US) population 
(approximately 63 million people) is between [ADDRESS_453381] an underlying medical condition that puts them at higher risk for 
influenza complications ( CDC 2019 ). In the US, the estimated rate of hospi[INVESTIGATOR_363926] 3-fold higher in adults 50 -64 year s of age compared to the younger adult (18 -49 
years) age group ( 155.1  vs 48.4 per 100,000). Furthermore, the estimated numbe r of medical visits 
due to influenza illnesses is even higher in the 50 -64 year s age group (3. 97 million) compared to 
older adults ( 1.72 million) (CDC 2018 -2019 ). While the effect of influenza vaccination on the high  
rates of mortality  and hospi[INVESTIGATOR_363927] 65 years and 
older, these issues remain an unmet medical need for adults as young as 50 years.  
In 2010, the Advisory Committee on Immunization Practices  (ACIP ) acknowledged  a high burden 
of influenza disease in individuals 50 to 64 years of age and as a consequence defined the risk 
group for older adults as 50 years  and older . In the [LOCATION_008]  ([LOCATION_006]) , the 20 20/2021 national 
influenza  vaccination program was extended to include adults 50 -64 of age ( NHS 2020 ). In 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 25 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
addition, several national government public health agencies (Austria, [LOCATION_013], Hungary, and 
Russia) issued recommendations for vaccination of all individuals of 60 years of age and above 
instead of ≥65 years of age  (Lang et al. 2012 ). 
Vaccination is considered the best approach to lower the burden of influenza disease. The efficacy 
in older individuals is significantly lower  due to the aging of the immune system (i.e. , 
immunosenescence ) and underlying medical conditions that can both increase the risk of influenza 
complications as well as interfere with immune responses ( Sasaki et al. 2011 ). Relatively low 
efficacy of conventional influenza vaccines in older adults provides an opportunity for vaccine 
improvement by [CONTACT_363954].  Older individuals have fewer naive B and 
T cells, more memory cells, and an increasing number of senescent cell s which are known to exert 
a regulatory role in vivo (Lang et al. 2012 ). Assuming the immune response becomes gradually 
weaker with age, and immune cells require a stronger stimulus, novel vaccine formulations are 
needed to elicit an effective vaccination -mediated immunity in older individuals ( Aiello et al. 
2019 ). 
One way to increase the immunogenicity of influenza vaccines is by [CONTACT_363946], such as the 
squalene and water emulsion adjuvant, MF59. Fluad®, Seqirus ’ trivalent seasonal influenza vaccine 
adjuvanted with MF59 (aTIV), is licensed for use in persons 65 years of age and above in Europe 
since 1997 and in the US since 2015. More recently, the quadrivalent version of Fluad (aQI V 
including A/H1N1, A/H3N2, B/Yamagata , and B/Victoria strains) is licensed in Australia (since 24 
Sep 2019), the US (since 21 Feb 2020), in the European Union (EU) including Iceland, Norway 
and Liechtenstein (since 26 May 2020), New Zealand (since Dec 202 0), and in the [LOCATION_006] for use in 
adults aged 65 years and older.  In multiple clinical studies, Fluad induced a significantly higher 
immune response compared to conventional nonadjuvanted influenza vaccines  in subjects aged 65 
years and older, including those w ith comorbidities  (Frey et al. 2014 ). 
The results of clinical studies conducted with Fluad (aTIV) in healthy individuals 50 -64 years and 
subjects 18 -60 years of age with chronic medical conditions demonstrated  similar ben efits to those 
observed  in adults 65 years of age and older in terms of immunogenicity (Baldo et al. 2007 ; 
O’Hagan et al. 2011 ; Noh et al. 2016 ). Similar to  the findings in older adults , an acceptable  safety 
and tolerability profile was seen in adults under 65  years of age.  
Apart from the medical need for improved vaccines in people aged 50 to 65 years,  determining 
persistence beyond a typi[INVESTIGATOR_363928], considering that influenza seasons 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 26 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453382] udy, adjuvanted quadrivalent influenza vaccine (aQIV), is an  
MF59 -adjuvanted egg -derived subunit inactivated quadrivalent influenza virus vaccine. A 0.5 -mL 
dose has been formulated to contain 15 μg hemagglutinin (HA) of each influenza virus strain,  
includi ng both A/H1N1 and A/H3N2 strains and strains of both B lineages.  
1.2 Rationale  
The aim of this study is  to demonstrate both a noninferior immune response as assessed by  
[CONTACT_190599] ( GMT ) ratio and seroconversion rate ( SCR ) difference for each strain and a 
superior immune response as assessed by  [CONTACT_363955] 2 of the 4 strains of aQIV 
compared with a license d nonadjuvanted quadrivalent influenza vaccine,  3 weeks after vaccination 
in adults 50 -64 years of age . In addition , immunogenicity, antibody persistence, reactogenicity and 
safety  will be assessed . Data from this study will be used to expand  the licensure of the 
quadrivalent version of Fluad  for the prevention of seasonal influenza in adults 50 -64 years of age.  
1.3 Potential Risks and Benefits  
Subjects will be exposed to aQIV or QIV vaccines.  
As with all injectable vaccines, immediate systemic allergic reactions to vaccination can  occur. The 
reactions for anaphylaxis are sporadic and estimated to be 1.3 per million vaccine  doses 
administered fo r all vaccines ( McNeil 2019 ). As a precautionary measure, all subjects  will remain 
under observation at the study site for at least 30 minutes after vaccination.  Vasovagal syncope 
(fainting) can occur before or after any vaccination, is usually triggered  by [CONTACT_363956] ; therefore, it is important that 
standard precautions and procedures be followed to avoid  injury from fainting. Intramuscular 
vaccination commonly precipi[INVESTIGATOR_14263] a transient and self-limiting  local inflammatory reaction. This 
typi[INVESTIGATOR_363929], erythema  (redness), or induration (hardness).  
aQIV vaccine  has been evaluated in two Phase [ADDRESS_453383] more severe and clinically 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 27 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
significant cases of influenza  disease during mis matched influenza seasons. The immune response 
following aQIV was similar to  the response after administration of the licensed MF59 -adjuvanted 
trivalent influenza vaccine  (aTIV). Immunogenicity was not previously determined with aQIV for 
subjects 50 -64 yea rs of age,  but studies with aTIV showed that the MF59 -adjuv anted vaccine was 
immunogenic in the full age  range for subjects ≥50 years of age  (Minutello et al. 1999 ). 
During clinical studies  with aQIV , the following side e ffects were very commonly reported (>1/10  
subjects): injection site pain, fatigue and headache  (Beran et al. 202 1; Essink et al. 2020 ). Common 
side effects (>1/100 subjects but  <1/10 sub jects) include: loss of appetite, diarrhea, nausea, 
arthralgia, myalgia, erythema,  induration, ecchymosis, and chills. Most of these side effects were 
mild or moderate and lasted for  3 days or less. A clinical immunogenicity and safety study with 
aTIV ( Study V7P38) showed  that the safety profile in the 50 -64 years age group was similar to that 
in the ≥65 years  age group ; however, reactogenicity of aQIV has not been assessed in adults 50 to 
64 years of  age. 
Based on the number of distributed doses, the cu mulative exposure to aQIV up to 30 November 
2020 is estimated to be around 17 million . As for all vaccines, severe allergic  reactions can occur.  
Please refer to the current Investigator ’s Brochure (IB)  for aQIV for a summary of potential  risks 
and expected  benefits , and to the Product Information for   for 
information regarding potential  risks and benefits of  the nonadjuvanted QIV . 
2 STUDY OBJECTIVES  
2.1 Primary Objective s 
 Primary Immunogenicit y Objectives  
1a. To demonstrate immunological noninferiority of aQIV versus a nonadjuvanted quadrivalent 
influenza comparator (QIV)  in subjects 50 -64 years of age, as measured by 

 
[CONTACT_98570] : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 28 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
hemagglutination inhibition (HI)4 geometric mean titers (G MTs) and seroconversion rates 
(SCR s) for each vaccine strain, at 3 weeks after vaccination.  
Success criteria:  
Noninferiority will be demonstrated if the upper limit ( UL) of the 95% confidence interval 
(CI) for the inter-group GMT ratio5 (QIV/aQIV) is ≤1.5 for each vaccine strain , and  the UL 
of the 95% CI for the difference in SCR6 (QIV-aQIV) is ≤10% for each vaccine strain.  
1b. To demonstrate that aQIV induces a superior immune  response compared with QIV in 
subjects [ADDRESS_453384] 2 of the 4 vaccine strain s. 
Success criteria:  
Superior immune response will be demonstrated if the UL of the 95% CI for  the inter-group 
GMT ratio ( QIV/aQIV ) is <1.[ADDRESS_453385] 2 of the 4  vaccine strain s. 
2.2 Secondary Objectives  
 Secondary Immunogenicity  Objective(s)  
2a. To demonstrate that aQIV induces a superior immune  response compared with QIV  in 
subjects [ADDRESS_453386] one  vaccine strain at 3 
weeks after vaccination.  
Success criteria:  
Superior immune response will be demonstrated if the UL of the 98.73% CI for  the inter-
group GMT ratio ( QIV/aQIV ) is <0.67 for one or more  vaccine strain s. 
                                                 
4 In ca se of lack of agglutination or agglutination mediated through neuraminidase for a specific strain using HI assay, 
immunogenicity for that strain will be assessed as measured by [CONTACT_363947] (MN) assay as an acceptable alternative.  
5 The GMT ratio is defined as the geometric mean of the postvaccination (Day 22) HI titer for QIV over the geometric mean of 
postvaccination HI titer for aQIV.  
6 The SCR is defined as the percentage of subjects with either a prevaccination HI  titer <1:10 an d a postvaccination HI titer ≥1: 40 
or a prevaccination HI  titer ≥1:10 and a ≥4 -fold increase in postvaccination HI titer. Difference in SCR is defined as SCR QIV- 
SCR aQIV. 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 29 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453387] one  vaccine strain at 
6 months after vaccination  with aQIV compared with  QIV as measured by [CONTACT_363957] 50 -64 years of age . 
Success criteria:  
Greater persistence of the immune response will be demonstrated if the UL of the 98.73% 
CI for  the inter-group GMT ratio (QIV/aQIV)  is <1.0 for one or more  vaccine strain s. 
2c. To evaluate the immunogenicity of aQIV compared with QIV as measured by [CONTACT_363958] 
50-64 years of age . 
 Secondary  Safety Objective(s)  
To assess the safety and reactogenicity of aQIV and QIV in adults 50 -64 years of age.  
2.3 Exploratory Objective s 
To evaluate persistence of the immune response at 9 months after vacci nation with aQIV 
compared with QIV as measured by [CONTACT_132370] 1 in subjects 50 -64 years of age.  
To further evaluate the immunogenicity of aQIV compared with  QIV in subjects 50 -64 
years of age , with alternative assays, if sera permit . 
3 STUDY DESIGN  
3.1 Overview of Study Design  
Experimental design:  This is a Phase 3, randomized, comparator -controlled, observer -blind, 
multicenter study in approximately 2,018 adults 5 0 to ≤64 years of age.  
Duration of the study:  The study duration is approximately [ADDRESS_453388].  
Vaccination schedule:  single vaccination (Day 1).  
Study vaccine:  aQIV vaccine.  
Comparator vaccines : nonadjuvanted QIV . 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 30 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
Treatment  groups:  
aQIV group: approximately 1,009 subjects receiving one dose of aQIV at Day 1.  
QIV group: approximately 1,009 subjects receiving one dose of QIV at Day 1.  
Randomization:  an Interactive Response Technology (IRT) system will be used in the study. 
Subjects will be enrolled and stratified equally into two age groups (50-≤59 years and 60-≤64 
years) with approximately 50% of subjects per age group. Within each age group , subjects will be 
randomized to aQIV or QIV according to a 1:1 ratio.  Stratification for history of any influenza 
vaccination within  the previous  3 influenza seasons (yes/no) will be applied to all subjects . 
Blinding:  Observer -blind study.  
Blood sample schedule:  Four blood samples (approximately 10 mL each)7 will be collected from all 
subjects on Days 1,  22, 181 and 271.  
Data collection:  electronic Diary (eDiary), electronic Case Reporting Form (eCRF).  
Study clinic visits:  Four clinic visits for each subject at Days 1, 22, 181 , and 271.  
Safety phone call : Two safety phone calls (Day 15 and Day 91) will be  conducted: on Day [ADDRESS_453389] any unsolicited adverse events ( AEs), including associated medications and any 
vaccinations, and on Day [ADDRESS_453390] only serious AEs (SAEs ), AEs leading to withdrawal, AEs of 
special interest (AESIs), and concomitant medications associated with these events  and any 
vaccinations . 
Solicited AEs  occurring on the day of study vaccination through the following 6 days (Day 1 
through Day 7, or longer if the events are not resolved ), will be recorded daily using an eDiary as 
completed by [CONTACT_423].  
                                                 
7 Subjects  at selected sites  may be asked to voluntarily provide extra blood sample s of 50 mL at Day 1 and Day 22 that 
can be used for future research not directly related to this study, but with the purpose to improve the understanding of 
the influenza vaccines or disease . 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 31 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
Safety data collection:  During the treatment period (Days 1 -22) a ll unsolicited AEs occurring 
within 21 days (Day 22) after study vaccination will be collected. During the follow -up per iod 
(Days 23 -271) only SAEs, AEs leading to withdrawal, and AESIs will be collected. These data will 
be captured by [CONTACT_363959] , during the safety phone calls 
schedule d to occur on Days 15 and 91 , and by [CONTACT_363960]. Subjects will be 
instructed to call the site in the event of any AE which they perceive as being of concern during the 
entire study period.  
Serological assays :  
HI8 assay for homologous vaccine strains, using egg-derived  target virus , will be performed for all 
subjects on serum samples collected on Days 1, 22, [ADDRESS_453391] 2 of the 4 strains of aQIV compared with a licensed nonadjuvanted quadrivalent 
influenza vaccine, 3 weeks after vaccinat ion in adults 50 -64 years of age. A superior immune 
response with a higher threshold (1.5 -fold) for the GMT ratio for at least one vaccine strain will 
also be evaluated, to further demonstrate an advantage for the adjuvanted vaccine. In addition, 
immunogenicity,  antibody persistence, reactogenicity and safety will be assessed.  
As for  adults of 65 years  of age and older , a high burden of influenza disease has been observed in 
individuals 50 to 64 years of age. Assuming the high rates of hospi[INVESTIGATOR_363930] s younger age group  are due to a weaker immune response 
                                                 
8 In case of lack of agglutination for a specific strain or aggl utination mediated through neuraminidase using HI assay, 
immunogenicity for that strain will be assessed as measured by [CONTACT_363947] (MN) assay as an acceptable alternative.  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 32 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
associate d with increasing age (i .e., immunosenescence ), the addition of an adjuvant such as  MF59 
may be beneficial , and may result in a grea ter immune response  similar to that observed in adults 
65 years of age and older . 
In this study we wil l compare an adjuvanted quadrivalent influenza vaccine (aQIV)  to a standard 
nonadjuvanted quadrivalent influenza vaccine (  to evaluate  if the 
addition of the adjuvant MF59 elicits  an immune response as strong as a standard nonadjuvanted 
quadri valent influenza vaccine, as well as result ing in a superior response for at least [ADDRESS_453392] beyond 6 months , immunogenicity at 6 and 9 months f ollowing vaccination  with aQIV or 
the nonadjuvanted vaccine will be compared to determine  if inclusion of MF59 results in greater 
duration of immune response.   
Data from this study will be used to expand the licensure of the quadrivalent version of Fluad  for 
the prevention of seasonal influenza in adults 50  to ≤64 years of age.  
3.3 Justification for Dose  
The selected dose and formulation of aQIV (15  μg of HA of each viral strain and 9.8 mg of MF59 
per dose) are well tolerated as demonstrated in previous studies. aTIV induces a higher immune 
response and has been associated with a higher effectiveness compared to nonadjuvanted influenza 
vaccine ( Domnich et al. 2017 ; Pebody et al. 2019 ). 
3.[ADDRESS_453393] study visit.  
3.5 Blinding Procedures  
The study is designed as an observer -blind study. During the treatment period of the study , 
designated and trained unblinded nurse(s), physician(s), or other qualified healthcare professional 
will be responsible for preparing and administering t he study vaccines to the subjects. They will be 
instructed not to reveal the identity of the study vaccines to the subject or to the investigative site 
personnel (i.e., blinded investigator and study nurse) involved in the monitoring of conduct of the 
trial, except in an emergency if unblinding in IRT is not possible. Vaccine administration should be 

 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 33 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453394] and blinded study personnel. The unblinded personnel should not be 
involved in data collection or data review such as safety assessme nts and/or collect study data after 
the vaccinations. Study vaccines will be assigned through an IRT system.  
Except in the case of medical necessity, a subject ’s treatment should not be unblinded without the 
approval of the Sponsor. In such instance, every  effort should be made to contact [CONTACT_152821]. If unblinding occurs, by [CONTACT_363961] , prior to completion of the study, the investigator must promptly contact [CONTACT_363962] t he circumstances in  the IRT system . In case of an emergency, the information can be 
retrieved by [CONTACT_363963] (a 24/7 backup service). 
If the subject or blinded site staff is unblinded by [CONTACT_093], the subject may be removed from 
an Analysis Set.  
All personnel involved in the conduct of the study or in the analysis of the final study results, or 
who have contact [CONTACT_363964], will remain blinded to the treatment codes until the clinical 
database has been locked , protocol deviations (except for Day 271 serum sample analysis PDs)  
have been assesse d, and the data have been  released for statistical analysis . The analysis on the 
primary and secondary objectives for the final CSR will be conducted on this data.  
All personnel involved in processing samples and performing laboratory assays will remain blinded 
to the treatment codes until all Day [ADDRESS_453395] over the duration of their study 
participation:  
• Demographic Information.  
• Medical History, including existing comorbidities.  
• Influenza vaccination history  within the previous 3 influenza seasons . 
• Physical examination including temperature , height, and weight.  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 34 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
• Reactogenicity: Solicited AEs for 7 consecutive days (or longer if the events are not resolved) 
following vaccination (Day 1 through Day 7).  
• Unsolicited AEs for 21 days following vaccination (Day 1 to Day 22).  
• SAEs, AEs leading to wit hdrawal from the study, and AESIs as collected from Day 1 to Day 
271. 
• Concomitant medications /vaccinations (as defined in  Section 6.5 , Prior and Concomitant 
Medications and Vaccines ). 
• Reason for early study termina tion (if applicable) . 
All data collected must only be identified using the Seqirus  Subject ID, as described in Section  
5.1.4, Randomization . 
 Tools Used for Data Collection  
Data will be recorded in the Subject Diary and collected on Case Report Forms ( eCRF s). 
Subject Diary  
Electronic Diaries (eDiaries), hereafter referred to as Subject eDiaries will be the only source 
document allowed for solicited local and systemic AEs (including body temperature 
measurements), starting  after the initial 30-minute  postvaccination period at the clinic , and 
continuing for 7 consecutive days (or longer if the events are not resolved). Refer to the user ’s 
manual for further details.  
The investigator (or delegated, Qualified HCP ) will review the Subject ’s eDiary data during eDiary 
use (Day 1 through Day 7) or longer if events are not resolved (up to 14 days after vaccination) . 
The investigator  (or delegated, Trained  HCP) will  also monitor the Subject ’s eDiary status for 
compliance on an ongoing basis during eDiary use (Day 1 through Day 7) or longer if events are 
not resolved  (up to 14 days after vaccination) . 
1. The Subject eDiary will be designed in such a way as to prevent any blank, incomplete or 
biologically implausible entries during e Diary completion. Subjects will be instructed to 
fully complete the Subject eDiary each day, as per the instructions provided.  
2. Before or just after vaccination, site staff must ensure that each subject’s eDiary is prepared 
for data capture in the ensuing p ostvaccination period.  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 35 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453396] be  entered on the AE page of the eCRF.  
 
Electronic Case Report Forms  
This study utilizes electronic Case Report Forms ( eCRF s) to collect study -related data from each 
subject. A qualified site staff member(s) is required to enter subject data in the eCRF s in English 
based on the medical informa tion available in each subject ’s source record.  
Data should be entered into the eCRF  in a timely fashion following each subject ’s clinic visit, study 
procedure, or phone call. Each subject ’s eCRF  casebook will be compared with the subject ’s source 
records by a Seqirus -approved study monitor (or designee) over the duration of the study in order to 
ensure data collection accuracy.  
3.[ADDRESS_453397] s in this study : 
• Blood at Days 1, 2 2, 181, and 271 . 
• Urine at Day [ADDRESS_453398] udy-specific Clinical Specimen 
Laboratory Manual for additional details.  
Blood Specimens  
Approximately 10 mL sample of blood will be drawn from all subjects at Visit 1 (Day 1)  before 
vaccination, and at Visit 3 (Day 22), Visit 5 (Day 181) , and Visit 6 (Day  271). The blood volume 
will not exceed 10 mL at each time point in order to provide the necessary serum volume 
(approximately half of the blood draw volume) for the serology assays.  
The blood will be used for immunological assays . See Section 7, Assessments  for additional detail s. 
The total amount of blood collected over the study period per subject will be 40 mL. 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 36 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453399] is eligible to provide extra blood sample s. 
Urine Specimens  
Urine will be collected for pregnancy testing in females of childbearing potential. Urine will be 
collec ted at Visit 1 (Day 1)  before vaccination.  
3.8 Stoppi[INVESTIGATOR_007]/Pausing Guidelines  
There are no predetermined stoppi[INVESTIGATOR_29200]. Subjects may be withdrawn from the study 
according to investigator discretion as described in Section 4.5, Premature Withdrawal from Study . 
3.[ADDRESS_453400] samples fo r the analysis of the secondary objectives will 
be taken at Visit 5 (Day 181) . The last clinical assessment for the s econdary safety objective will be 
at Visit 6 (Day 271). Accordingly, f or the purpose of this protocol, end of study is defined as the 
compl etion of the testing of the Visit 5 (Day 181 ) biological samples, to be achieved no later than 
[ADDRESS_453401] biological sample at Visit 5 (Day 181), or the Last Subject Last 
Visit , whichever is late r. The local end of the study is d efined as the Las t Subject Last Visit within 
the country.  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 37 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453402] meet ALL of the inclusion criteria described.  
1. Individuals 50 to 64 years of age (i.e. 50 to ≤64 years) on the day of informed consent;  
2. Individuals who have voluntarily given written consent after the nature of the study has been 
explained according to local regulatory requirements, prior to study entry;  
3. Individuals who can comply with study  procedures including follow -up9; 
4. Males, females of non -childbearing potential10 or females of childbearing potential who are 
using an effective birth control method11, at least [ADDRESS_453403] not meet ANY  of the exclusion criteria 
described  below:  
1. Females of childbearing potential who are pregnant, lactating, or who have not adhered to a 
specifi ed set of contraceptive methods  from at least 30 days prior to study entry and who do 
not plan to do so until 2 months after the study vaccination ; 
2. Progressive, unstable or uncontrolled clinical conditions ; 
                                                 
[ADDRESS_453404] occurred after hysterectomy, after bilater al 
oophorectomy, or iatrogenic ablation of ovarian function . 
11 The following birth control methods are considered effective: abstinence, hormonal contraception (such as oral, injection, 
transdermal patch, implant) if used for at least [ADDRESS_453405] six months prior to informed consent . 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 38 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
3. Hypersensitivity, including allergy, to an y component of vaccines, medicinal products or 
medical equipment whose use is foreseen in this study ; 
4. History of any medical condition considered an AESI (see  APPENDIX 2 – List of Adverse 
Events of Special Interest ); 
5. Known history of Guillain Barré syndrome or another demyelinating disease such as 
encephalomyelitis and transverse myelitis;  
6. Clinical conditions representing a contraindication to intramuscular vaccination and blood 
draws ; 
7. Abnormal function of the immune system resulting from:  
a. Clinical conditions ; 
b. Systemic administration of corticosteroids (PO/IV/IM)12 at a dose equivalent to 
≥20 mg/day of prednison e for more than 14 consecutive days within 90 days prior to 
informed consent. Topi[INVESTIGATOR_2855], inhaled and intranasal corticosteroids are permitted. 
Intermittent use (one dose in 30 days) of intra -articular corticosteroids is also 
permitted;  
c. Administration of antineoplastic and immunomodulating agents or radiotherapy 
within 90 days prior to informed consent ; 
8. Received immunoglobulins or any blood products within 180 days prior to informed consent ; 
                                                 
12 PO= by [CONTACT_1966]; IV=intravenous; IM= intramuscular  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 39 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453406] of this study (note s: i. concomitant participation in a study not 
involving or no longer involv ing administration of drugs, vaccines, or medical devices, is 
acceptable (e.g. studies in safety follow -up phase, observational studies ); ii. concomitant 
participation in a COVID -19 vaccine  study is acceptable provided that  the vaccine dosing 
interval ment ioned in Exclusion Criterion #11 is adhered to ); 
10. Receipt of any influenza vaccine within 6 months prior to enrollment in this study, or plan to 
receive influenza vaccine during the study period;  
11. Receipt of  any (investigational or licensed)  COVID -19 vaccine  within 14 days (non -replicating 
vaccines) or 28 days (replicating vaccines) prior to enrollment or plan to receive any COVID -
19 vaccine within 7 days from study vaccination;  
12. Receipt of any inactivated non -influenza vaccine within 14 days or live-attenuated vaccine  
within 28 days prior to enrollment in this study or plan to receive any other non -influenza 
vaccine within 28 days from study vaccination;  
13. Acute (severe) febrile illness (See Section 4.3, Crite ria for Delay of Vaccination ); 
14. Any other clinical condition that, in the opi[INVESTIGATOR_871], might interfere with the 
results of the study or pose additional risk to the subject due to participation in the study;  
15. Study personnel or immediate family members or household member of study personnel.  
4.[ADDRESS_453407] a 
transient clinical circumstance, such as an infection, which may warra nt delay of vaccination: body 
temperature elevation  (≥38.0 ° C [≥100.4 °F]) within 3 days prior to intended study vaccination], or 
prophylactic  use of antipyretics and/or analgesic medications within [ADDRESS_453408] may be considered eligible for study enrol lment after the 
appropriate window for delay has passed and inclusion/exclusion criteria have been rechecked, and 
if the subject is confirmed to be eligible.  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 40 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453409] effects occur and/or for safety reasons. In addition, a subject may 
be withdrawn by [CONTACT_363965]/she violates the study plan or for 
administrative reasons. The investigator or study coordinator must notify the Sponsor immediately 
when a subject has been wit hdrawn due to an AE. 
The circumstances above are referred to as premature withdrawal from the study, and the reason for 
premature withdrawal should be clearly documented and detailed in the source documentation. The 
investigator should make every attempt to evaluate the subject ’s safety, including resolution of 
ongo ing AEs, at the time of premature withdrawal. If a subject wants to withdraw from the study 
prior to the last planned study visit, the subject will be asked to be followed for safety for the 
duration of the study. When a subject withdraws, or is withdrawn,  from the study, the procedures 
described in Section 5.6.1, Early Termination Visit  should b e completed if possible.  
Any subject who becomes pregnant during the study, despi[INVESTIGATOR_363931], should be encouraged to continue participating in the study for safety  follow -up. The 
site must record a confirmation of pregnancy in the eCRF and must complete  a Pregnancy 
Report ing/Outcome  Form as soon as possible after learning o f pregnancy occurrence (see  Section 
7.1.6, Pregnancies  for further details). If the pregnant subject withdraws from the  study for any of 
the below categories except death, the site will obtain permission from the  subject to continue to 
remain in contact [CONTACT_363966], even if the outcome is not 
known until after the subject reaches the end of the follow -up period.  
The reasons for premature withdrawal from the study include: AE, death, withdrawal of consent, 
lost to follow -up, and protocol deviation. These reasons are described in greater detail below.  
Adverse Event 
For any subject withdrawn from study participation prior to the planned Study  Completion  Visit, it 
is important to determine if an AE was associated with the reason for discontinuing the study. This 
AE must be identified on the AE eCRF  page by [CONTACT_124439] “Withdrawn from study due to AE ”. Any 
ongoing AEs at the time of study withdrawal must be followed unt il resolution or stabili zation.  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 41 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453410] is otherwise entitled . Reason for early termination should be deemed 
as “withdrawal of consent ” if the subject withdraws from participation due to a non -medical reason 
(i.e., reason other than AE). If the  subject  intends to withdraw consent from the study, the 
investigator should clarify if the subject will withdraw completely from the study or if the subject 
will continue study participation for safety, or a subs et of other study procedures. If the subject 
requests complete withdrawal from the study, no further study interventions will  be performed with 
the subject.  
Lost to Follow -Up 
For subjects who fail to show up for planned  visits (clinic or telephone contacts), study staff are 
encouraged to make at least three documented attempts to contact [CONTACT_363967]. These efforts to contact [CONTACT_363968]. The termination date for the subject to be captured on the Study Completion  eCRF  page 
is the date of the last  successful  contact (clinic visit or telephone) wi th the subject.  
Other Reason s 
Examples for subjects withdrawn from the study due to an “other ” reason can include: Sponsor 
decision to terminate the study, subject meeting a prespecified withdrawal criterion, subject 
discontinuation for insurance issues, m oving, no time, etc. This reason should be noted in the Study 
Completion  eCRF  page and any ongoing AEs at the time of study withdrawal must be followed 
until resolution/stabilization.   
Study Terminated by [CONTACT_363969], the investigator is to promptly 
inform the study subjects and local Ethics Committee ( EC)/Institutional Review Board ( IRB) and 
should assure appropriate therapy and follow up for the subjects.  All procedures and requirements 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 42 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
pertaining to the archiving of study documents should be followed. All other study materials (study 
medication/vaccines, etc.) must be returned to the Sponsor.  
5 STUDY PROCEDURES  
The sections that follow provide an overview o f the procedures that are to be followed in enrolling, 
evaluating, and following subjects who participate in this clinical study. Visits can be either clinic 
visits or safety follow -up telephone calls , as specified in the Study Procedures table ( Table 5-1) and 
in the Time and Events Schedule ( Table 0-1). 
There is a potential risk of exposure to coronavirus for the subject and site staff during the study. 
Risk to exposure should be managed according to local/national or institutional COVID -19 
guidelines.  
Table 5-1: Study Procedures  
Visit Category  Procedures  
Prevaccination Procedure (s) and Vaccination 
Clinic Visit  Section 5.1  describes procedures to be 
followed prior to study vaccination: informed 
consent, screening, enrolment,  blood draw and 
randomization . Section 5.2  and Section 5.3  
describe procedures to be followed during the 
clinic visit involving vaccination: vaccination, 
and postvaccination procedures  
Postvaccination Visit s  Section 5. 4 describes follow -up clinic visits 
and safety  follow -up calls  
Study Completion/ Termination Visit  Section 5.[ADDRESS_453411] 
(may include early termination visit)  
 
5.1 Prevaccination  Procedures : Screening/Randomization  
This section describes the procedures that must be performed for each potential subject prior to 
vaccination, including obtaining informed consent, screening, enrol lment , and randomization.  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 43 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453412] 
sufficient knowledge and understanding of the nature of the proposed researc h, the anticipated risks 
and potential benefits, and the requirements of the research to be able to make an informed 
decision.  
Informed consent following local IRB/ EC guidance must  be obtained before conducting any study -
specific procedure (i.e., all of th e procedures described in the protocol ). The process of obtaining 
informed consent should be documented in the subject source document  in addition to maintaining 
a copy of the signed and dated informed consent.  
If a subject  is unable to read, an impartial witness should be present during the entire informed 
consent discussion. An impartial witness is defined as a person who is independent from study 
conduct, who cannot be unfairly influenced by [CONTACT_363970], who attends the 
informed consent  process if the subject or the subject's legally acceptable representative cannot 
read, and who reads the informed consent form and any other written information supplied to the 
subject. After the written informed consent form and any other written informa tion to be provided 
to subjects, is read and explained to the subject and after the subject  has verbally consented to the 
subject ’s participation in the study and, if capable of doing so, has signed and personally dated the 
informed consent form, the witne ss should sign and personally date the consent form. By [CONTACT_313996], the witness attests that the information in the consent form and any other written 
information was accurately explained to, and apparently understood by, the subject and that  
informed consent was freely given by [CONTACT_423].  
 Screening  
After an individual has consented to participate in the study and informed  consent  is signed, that 
individual will be given a unique Screening Number  which is a consecutive number  assigned  by [CONTACT_2924] . The subject ’s unique Screening Number will be documented in the Screening and 
Enrolment log  only. The eligibility of the subject will be determined based o n the inclusion and 
exclusion criteria listed in Section 4, Selection of Study Population  and evaluated during this 
screening procedure.  
Prior to study enro llment, demographic data will be collected from the subject, including: age, sex , 
race and ethnicity, and influenza vaccination  history  in the last 3 years . 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 44 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453413] eligibility for study participation such as prior vaccinations, concomitant 
medicati ons, and previous and ongoing illnesses or injuries. Relevant medical history can also 
include any medical history that contributes to the understanding of an AE that occurs during study 
participation, if it represents an exacerbation of an underlying dise ase/pre -existing problem.  In case 
a subject is recruited from outside the clinic, and the investigator  despi[INVESTIGATOR_363932] ’s medical history and associated concomitant medications , verbal recall of 
medical history  and a ssociated concomitant medication is acceptable.  
If applicable, p rior and concomitant medication s or vaccinations taken prior to start of study should 
be collected  (refer to Section 6.5, Prior and Concomitant Medica tions and Vaccines  for further 
detail s). The use of  any prophylactic systemic analgesics and/or antipyretics within 24 hours prior 
to vaccination is a criterion  for delay of vaccination (see  Section 4.3, Criteria for Delay of 
Vaccination ). 
Also, data to quantify the risk of complications from influenza will be collected. The ‘Prediction  
Rule for Estimating the Probability of Hospi[INVESTIGATOR_363933] ’ (Hak et al. 2004 ; see APPENDIX 1 – Prediction Rule ) will be used. The risk 
assessment, which  incorporates medical comorbidity among other b aseline characteristics such as 
outpatient visits  during previous year and previous hospi[INVESTIGATOR_363934], 
is a validated  predictor of risk of complications from influenza in elderly subjects. Using this 
prediction rule, a  score of  <50 is considered low risk and a score of ≥50 is considered high risk of 
complications  from influenza in elderly subjects. Assessment of pre -existing medical conditions 
should be made  by [CONTACT_363971].  
Prevaccination body temperature (preferably oral) will be collected. If body temperature is  
≥38.0°C/≥100.4 °F at the time of screening, vaccination must be postponed until 3 days after the  
fever has resolved (see Secti on 4.3, Criteria for Delay of Vaccination ). Height and weight will also  
be measured. For females of childbearing potential, a pregnancy test should be performed (see  
Section 3.7, Collection of Clinical Specimens ). 
Review of systems is a structured interview that queries the subject as to any complaints the subject 
has experienced across each organ system. This will be performed before enrolment and used to 
guide a physical examination.  
A general physical examinatio n is to be performed by a qualified healthcare professional, who is  
identified within the Study Staff Signature [CONTACT_94618]. These data will be written in the source document 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 45 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
(see Section 9.1, Source Documentation ). Should the physical assessment reveal any abnormal 
values or events, these must be documented in the Medical History eCRF . 
Prior to vaccination, approximately 10 mL of blood will be drawn from all subjects for serology, 
testing . Refer to  Section 3.7, Collection of Clinical Specimens . 
In the event that the individual is determined ineligible for study participation, he/she is considered 
a screen failure. The reason for screen failure must be document ed in the Screening and Enrol lment 
log. If the individual is determined to be eligible for the study, he/she will be enrolled into the 
study.  
 Enro llment  
After signing the ICF, if an individual is determined to be eligible for study participation, the 
inves tigator will enro ll the subject using  Interactive Response Technology (IRT) system . 
Stratification information should be provided before randomization.  
 Randomization  
Enrolled subjects will be assigned a subject ID and randomized in the IRT system in a 1:1 ratio to  
receive either aQIV or QIV with age (50 to ≤59, and 60 to ≤64 years  of age ), and history of any 
influenza vaccination within  the previous  3 influenza seasons (yes/no) as stratification factors.  The 
Subject ID will be the subject ’s unique identific ation number for all eCRF s and associated study 
documentation that will be used for duration of the study. After randomization, the Screening 
Number ceases to be used and remains in the Screening and Enrol lment Log only . The list of 
randomization assignmen ts is produced by [CONTACT_363972] (SOP).  
If for any reason, after signing the informed consent form (ICF) , the subject who is eligible and 
enrolled  fails to be ra ndomized, this is called a randomization failure and the early termination 
study procedures must be applied. T he reason for all randomiz ation failures  should be  recorded in 
the Screening and Enro llment Log and in the source document. The information on sub jects who 
are randomization failures should be kept distinct from subjects who are screen failures , as 
described in Section 5.1.2, Screening . 
If for any reason, after randomization the subject fails to undergo treatment  or the subject has 
discontinued,  the reason  should be  recorded in source document  and in the eCRF.  The information 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 46 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453414] in the source do cumentation from randomization 
failures . 
 Blood Draw  
After randomization, but pr ior to vaccination, a pproximately  10 mL of blood will be drawn from all 
subjects (see Section 3. 7, Collection of Clinical Specimens ). Additionally, an extra blood sample of 
[ADDRESS_453415]  sponsored approved S OPs/Instructions (or provided by [CONTACT_456]) for con ducting home  
visits and the collection of blood samples in the home setting, prior to the home visit  occurring. 
These procedures may also need to be approved by [CONTACT_779] ’s IRB/EC  depending on local and 
country regulations.  
5.[ADDRESS_453416] 
according to the procedures described in Section 6.3, Vaccine Preparation and Administration . 
Observe the blinding procedures described  in Section 3.5, Blinding Procedures . 
5.3 Postvaccination Procedures  
The following p ostvaccination procedures will be performed on Day 1. 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 47 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453417] 30 minutes , including observation for 
immediate postvaccination AEs (unsolicited). All safety data collected during this t ime will be 
recorded in the subject ’s source document and in the Adverse Event s eCRF.  
Subject Diary Training  
A Subject eDiary will be dispensed to subjects  (provisioned device or as an app on their own 
device)  in this study to document solicited AEs. The Subject eDiary is the primary  source for 
collection of these data; therefore, it is critical that the subject completes the Subject eDiary 
correctly. The subject should be trained on  how and when to complete  each field of the Subject 
eDiary.  
The subj ect should be trained  on how to self-measure local solicited AEs and body temperature  
(preferably oral) . The measurement of solicited local AEs is to be performed using the ruler 
provided by [CONTACT_779].  
The subject  should be instructed how to perform body te mperature measurement using the 
thermometer provided by [CONTACT_779].  If the subject feels unusually hot or cold during the day, the 
subject  should check body temperature. The highest body temperature observed that day should be 
recorded in the Subject eDiary . 
Subject eDiary t raining should be directed at the individual (s) who will perform the measurements 
of AEs and who will enter the information into the Subject eDiary. In some  situations, the Subject 
eDiary may be completed by [CONTACT_363973] , e.g.  caregiver, spouse, partner 
(except study site personnel). If a person other than the subject  enters information into the Subject 
eDiary, the reason that the subject cannot complete their  own eDiary and the person ’s identity and 
relationship to the s ubject must be documented in  the subject ’s source  document . Any individual 
who makes entries into the eDiary must receive training  on completion of the eDiary at the time of 
the visit. This training must be documented in the  subject ’s source  document . Idea lly, the same 
individual should complete the eDiary throughout the  course of the study. Refer to the study -
specific eDiary Manual for additional details on the  assignment and use.  
Subject Compliance:  Subjects should start to complete the eDiary on the day of vaccination for 
7 consecutive  days after vaccination  (Day 1 to Day 7) . If a solicited local or systemic AE continues 
beyond day [ADDRESS_453418] eDiary  will be continued until the event(s) 
resolved or for a maximum of 14 days after vaccination.  If the reaction continues to be present after 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 48 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
Day 14, the event and follow -up is to be captured as an unsolicited AE in the eCRF. Reminders will 
be sent every day via the electronic device (smartphone) and diary data should be submi tted every 
day. Subject s must be contact[CONTACT_363974] [ADDRESS_453419] has a medical condition that leads to a hospi[INVESTIGATOR_363935]  (or as soon as the subject is medically stable)  or to a visit to/by a doctor or is otherwise 
of concern . 
 eDiary Reminder Alert s 
The subject will receive daily reminders via the Subject eDiary built -in audio -visual alarms to alert 
the user to complete the eDiary during the postvaccination period. From Day  [ADDRESS_453420] any solicited AEs, and the presence  of any  unsolicited 
AEs (yes/no) , and whether these AEs were medically attended ( (yes/no) , defined as symptoms or 
illnesses requiring hospi[INVESTIGATOR_059], or emergency room visit, or visit to/by a qualified  healthcare 
professional ). In case of such events, subjects will be instructed to contact [CONTACT_363975](s).  
The Subject eDiary system may also allow for regular alerts to be issued via email to site staff 
indicating where subjects may need to be contact[CONTACT_363976]:  
• Non-compliance (i.e. failing to enter or transmit diary data),  
• Reporting of any severe so licited reactions  (one or more) that may suggest the need for  
medical support (as per medical judgement of the qualified healthcare professional) , 
• Subject experienced an unsolicited AE that was medically attended.  
Sites must assess these alerts when received and contact [CONTACT_363977].  Contact [CONTACT_363978]. Please refer to  Section 4.5, Premature 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 49 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
Withdrawal from the Study  and Section 7.1.3, Evaluation of Adverse Events  for guidance on 
necessary action in the event of one of these alerts.  
5.4 Postvaccination Visit s 
Postvaccination clinic visits or safety phone calls will be performed on  Day 15 (Safety Phone Call),  
Day 2 2 (Clinic Visit), Day 91 (Safety Phone Call) , Day 181 (Clinic Visit) , and Day 271 (Clinic 
Visit).  
 Follow -up Clinic Visit(s)  
Postvaccination clinic visits  will be performed on Day 22 (Visit 3) , Day 181 ( Visit 5) , and Day 271 
(Visit 6) (see Section 5.6, Study Completion/Termination Visit  for assessment s to be performed at 
the study completion visit) . 
In the exceptional situation in which a clinic visit is not possible  at Day 22 and/or Day [ADDRESS_453421] will be interviewed by a qualified 
healthcare profess ional  to determine if any unsolicited AEs occurred , including SAEs and AESIs,  
and if any concomitant medications or vaccines were taken/received in the time since the last 
contact . The qualified healthcare professional reviewing these data will discuss the  symptoms (if 
any) reported by  [CONTACT_178013]/or AEs are present. 
Adverse events reported by [CONTACT_363979] -up clinic visit must be recorded in the 
subject's source document and on an Adverse Even ts eCRF , as specified  in Section 7.1, Safety 
Assessments . 
A symptom -directed physical examination will be performed , if necessary , according to symptoms 
the subject has reported. This physical examination will include an examination of organ systems 
that are relevant to the investigator based on review of the subject ’s reported AEs, and/or 
concomitant medication use. The physical assessment must be performed by [CONTACT_363980], who is qualified to perform a physical assessment in accordance with 
their institutional policy. Corresponding information is documented in the subject ’s source 
document and eCRF (s). 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 50 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453422] will be asked to return any ele ctronic device that was provisioned for the  collection of 
the solicited AEs, if applicable. If the eDiary application was installed on a  personal phone, it will 
be removed. During the visit, approximately 10 mL of blood will be  drawn from all subjects (see  
Section 3.7, Collection of Clinical Specimens ). Additionally, an extra blood sample of [ADDRESS_453423] the site 
immediately (or as soon as the subject is medically stable) if the subject has a medical condition 
that leads to a hospi[INVESTIGATOR_059] , an emergency room visit  or has any other  concern . 
Day [ADDRESS_453424] will be inte rviewed by a qualified 
healthcare professional to determine if any SAEs, AESIs, or  AEs leading to withdrawal  occurred 
and if concomitant medications associated with those events or any vaccinations were 
taken/received  in the time since the last contact. A ll AEs reported by [CONTACT_363979] -up 
clinic visit must be recorded in the subject's source document and only SAEs, AESIs, or AEs 
leading to withdrawal must be documented on an Adverse Events eCRF, as specified in Section 7.1, 
Safety Assessment . 
A symptom -directed physical examination will be performed, if necessary, according to symptoms 
the subject has reported. This physical examination will include an examination of organ sys tems 
that are relevant to the investigator based on review of the subject ’s reported AEs, and/or 
concomitant medication use. The physical assessment must be performed by [CONTACT_363980], who is qualified to perform a physic al assessment in accordance with 
their institutional policy. Corresponding information is documented in the subject ’s source 
document and eCRF(s) . 
During the visit, approximately 10 mL of blood will be drawn from all subjects (see Section 3.7, 
Collection of Clinical Specimens ). 
The site should schedule the next study activity, a clinic visit  on Day 271 (see Section 5.6, Study 
Completion/Termination Visit  for as sessments to be performed at the study completion visit) , with 
the subject. The subject will be reminded to contact [CONTACT_363981] : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 51 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
the site immediately (or as soon as the subject is medically stable) if the subject has a  medical 
condition that leads to a hospi[INVESTIGATOR_059], an emergency room visit or has any other concern.  
 Safety Follow -up Calls  
Safety follow -up calls will be performed on Day [ADDRESS_453425] by a qualified healthcare professional 
designated on the site ’s Roles and Responsibilities  log. These calls will follow a script which will 
facilitate the collection of relevant safety information.  The subject  will be interviewed according to 
the script, and information relating to the following AEs will be collected:  
Day [ADDRESS_453426] the site 
immediately (or as soon as the subject is medically stable) if the subject has a medical condition 
that leads to a hospi[INVESTIGATOR_363936] a visit to/by a doctor or has any 
other concern. Contact [CONTACT_363982]/event must be documented in the subject ’s 
source record.  
Day [ADDRESS_453427] the site 
immediately (or as soon as the subject is medically stable) if the subject has a medical condition 
that leads to a hospi[INVESTIGATOR_363937] . Contact 
[CONTACT_363982]/event  must be documented in the subject ’s source record . 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 52 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
5.5 Unscheduled Visits  
Not applicable.  
5.6 Study C ompletion/Termination Visit  
The study completion  visit will occur on Day [ADDRESS_453428] (clinic visit or telephone call) in which the 
subject ’s health status was assessed or, in cases where the subject does not agree to any further 
safety follow -up, it is th e date consent is withdrawn. This date should be recorded on the Study 
Completion  eCRF  page. For visit procedures to be performed for a subject whose planned study 
participation ends prematurely, please see Secti on 5.6.1, Early Termination Visit . 
During the study completion  visit, the subject will be interviewed by a qualified healthcare 
professional to determine if any SAEs, AESIs, or  AEs leading to withdrawal , occurred and if 
concomitant medications associated with those events  or any vaccinations  were taken/received  in 
the time since the last contact. Adverse events reported by [CONTACT_363979] -up clinic visit 
must be recorded in the subject's source document and only SAEs, AESIs, or AEs leading to 
withdrawal must be documented on an Adverse Events eCRF, as specified in Section 7.1, Safety 
Assessment . 
A symptom -directed physical examination will be performed, if necessary, according to symptoms 
the subject has rep orted. This physical examination will include an examination of organ systems 
that are relevant to the investigator based on review of the subject ’s reported AEs, and/or 
concomitant medication use. The physical assessment must be performed by [CONTACT_363983], who is qualified to perform a physical assessment in accordance with 
their institutional policy. Corresponding information is documented in the subject ’s source 
document and eCRF(s).  
During the visit, approximately 10 m L of blood will be drawn from all subjects (see Section 3.7, 
Collection of Clinical Specimens ). 
The site will review with the subject the plan of when information relating to the subject ’s 
participation in the stu dy may be available (e.g., study results, treatment assignments). It will also 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 53 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453429] ’s participation in the study will be shared with 
the subject ’s healthcare provider, if the  subject  chooses to share this inf ormation.  
The site will complete the Study Completion  eCRF  page and this will mark the completion of the 
subject ’s participation in the study.  
 Early Termination  Visit  
When a subject is withdrawn  from treatment or withdraws from the study , the investigator will 
notify the Sponsor  and, when possible, will perform the procedures as described in Section 5.6 
Study Completion/Termination Visit . The reason(s) for the early termination will b e included in the 
subject ’s source documentation. If the Early Termination Visit is a telephone call, collect as much 
information as possible. Early Termination Visits include subjects who were randomized but not 
treated.  
The site will review with the subject the plan of when information relating to the subject ’s 
participation in the study may be available (e.g., study results, treatment assignments). It will also 
be discussed how information relating to the subject ’s participation in the study will be shar ed with 
the subject ’s healthcare provider, if the subject  chooses to share this information.  
The site will complete the Study Completion  eCRF  page and this will mark the completion of the 
subject ’s participation in the study.  
[ADDRESS_453430] not be administered to subjects,  as specified in 
Section 6 .6, Vaccine Supply, Labeling, Storage and Tracking . 
6.1 Study Vaccine(s)  
The term ‘study vaccine ’ refers to those vaccines provided by [CONTACT_1034], which will be evaluated 
as part of the study objectives. The study vaccines specific to this study are described in the 
following sections . 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 54 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
Investigational Vaccine: aQIV  (Fluad Tetr a/Quadrivalent)  
A 0.5 mL dose of aQIV (quadrivalent MF59C.1 adjuvanted influenza vaccine) contains nominally  
15 μg of HA of each of the 2 influenza type A strains and each of the 2 influenza  B strains with a 
total of 60 μg of HA in the vaccine. The strain composition will be that  recommended by [CONTACT_363984]. The full 
composition of the vaccine is reported in Table 6-1. 
  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 55 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
Table 6-1: aQIV Vaccine (Fluad Tetra/Quadrivalent) Composition  
Names of Ingredients  Quantity per dose*  Function  
Active Ingredients  
HA and NA antigens from the influenza virus strains 
recommended by [CONTACT_14300] / CBER/ CHMP for the 
manufacture of influenza vaccine for season  
A/ (H1N1)  
A/ (H3N2)  
B/ (Yamagata lineage)  
B/ (Victoria lineage)  nominally 15  g HA/strain  Active ingredient  
Adjuvant    
Squalene  9.75 mg Oil phase  
Polysorbate 80  1.175  mg Surfactant  
Sorbitan trioleate  1.175  mg Surfactant  
Sodium citrate  0.66 mg Buffer  
Citric acid  0.04 mg Buffer  
Other Ingredients    
Sodium chloride   Isotonic aid  
Potassium chloride   Buffer  
Potassium dihydrogen phosphate   Buffer  
Disodium phosphate dihydrate   Buffer  
Magnesium chloride hexahydrate   Stabilizer  
Calcium chloride dihydrate   Stabilizer  
Water for injection  up to 0.50  mL Diluent  
**  
Volume of Formulation  0.5 mL 
Appearance  Liquid, milky -white suspension  
Vaccine Presentation  Pre-filled  syringe  
Abbreviations: aQIV = adjuvanted Quadrivalent Influenza Vaccine; CBER = Center for Biologics Evaluation and Research; CHMP 
= Committee for Medicinal Products for Human Use; HA = hemagglutinin; NA = neuraminidase; WHO = World Health 
Organization.  
Notes:  
* The quantities indicated in this table reflect the amount in a 0.5 mL dose.  
** Residues of special relevance: cetyltrimethylammonium bromide  (CTAB), chicken proteins, such as ovalbumin, formaldehyde, 
kanamycin and neomycin sulphate.  
 

 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 56 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
Comparator Vaccine:   (nonadjuvanted QIV ) 
A 0.5 mL dose of  nonadjuvanted quadrivalent influenza vaccine contains nominally 15 μg of HA of 
each of the 2 influenza type A strains and each of the 2 influenza B strains with a total of 60 μg of 
HA in the vaccine. The strain composition will be that recommended by [CONTACT_363985].  The full composition of the vaccine 
is reported in Table 6-2. 
Table 6-2:  Composition  
Names of Ingredients  Quantity per dose*  
Active Ingredients  
HA and NA antigens from the influenza virus strains 
recommended by [CONTACT_14300] / CBER/ CHMP for the 
manufacture of influenza vaccine for season  
A/ (H1N1)  
A/ (H3N2)  
B/ (Yamagata lineage)  
B/ (Victoria lineage)  nominally 15  g HA/strain  
Other Ingredients   
Sodium chloride  3.75 mg  
Disodium phosphate dodecahydrate  1.3 mg  
Potassium dihydrogen phosphate  0.2 mg  
Potassium chloride  0.1 mg  
Magnesium chloride hexahydrate   
Water for injection   
Octoxynol -10 (TRITON X -100) ≤0.115 mg  
α-tocopherol hydrogen succinate  ≤0.135 mg  
Polysorbate 80 (Tween 80)  ≤0.550 mg 
*  
Volume of Formulation  0.5 mL 
Appearance  Colo rless to slightly opalescent  suspension  
Vaccine Presentation  Pre-filled  syringe  
* Residues of special relevance: hydrocortisone , gentamycin sulfate, ovalbumin, formaldehyde , and sodium deoxycholate . 
 

 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 57 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
6.2 Non-Study Vaccines  
Non-study vaccines will not be provided by [CONTACT_363986] . 
6.3 Vaccine Preparation and Administration  
The investigator or designee will be responsible for oversight of the administration of vaccine to 
subjects enrolled in the study according to the procedures stipulated in this study protocol. All 
vaccines will be  administered only by [CONTACT_363987].  
Detailed vaccine preparation and administration instructions will be provided to investigators prior 
to study start , and will also be available in the Investigator Pharmacy Manual.  
Both vaccines are to be provided in pre -filled syringes, each with an injectable volume of  
approximately 0.5 mL. The full volume contained in the pre-filled syringes  is to be administered.  
Vaccination will be performed intramuscularly, preferably in the deltoid muscle of the nondominant  
arm. 
PRECAUTIONS TO BE OBSERVED IN ADMINISTERING STUDY V ACCINE:  
Prior to vaccination, subjects must be determined to be eligible for study vaccination and it must be 
clinically appropriate in the judgment of the investigator to vaccinate. Eligibility for vaccination 
prior to first study vaccine administration is determined by [CONTACT_363988] 4.1, Inclusion Criteria  and 4.2, Exclusion Criteria . 
Delay of  study vaccination is determined by [CONTACT_363989] 4.3, Criteria 
for Delay o f Vaccination . 
Study vaccines should not be administered to individuals with known hypersensitivity to any 
component of the vaccines.  
Standard immunization practices are to be observed and care should be taken to administer the 
injection intramuscularly . Before administering vaccine, the vaccination site is to be disinfected 
with a skin disinfectant (e.g., 70% alcohol). Allow the skin to dry. The vaccine must  NOT be 
injected intravascularly.  
As with all injectable vaccines, trained medical personnel and appropriate medical treatment should 
be readily available in case of anaphylactic reactions following vaccine administration. For 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 58 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
example, epi[INVESTIGATOR_238] 1:1000, diphenhydramine, and/or other medi cations for treating anaphylaxis 
should be available.  
6.4 Vaccine Administration Error or Overdose of Vaccine  
Vaccine administration error is defined as receiving a dose of study vaccine that was administered 
by a different route from the intended route of adm inistration. An overdose of study vaccine 
(whether accidental or intentional) is defined when a dosage higher than the recommended dosage 
is administered in one dose of study vaccine as per dosing regimen described in Section 6.1, Study 
Vaccines . 
Any vaccine administration error or overdose of study vaccine detailed in this protocol must be 
reported as an AE, and if the vaccine administration error or overdose is associated with a n SAE, it 
must be reported as such within  [ADDRESS_453431] ’s influenza vaccination history from the [ADDRESS_453432] ’s source records  and in the eCRF . 
Information on  whether the subject was vaccinated in the last 3 years (yes/no), including the type  of 
vaccination (if available)  should be documented . In addition, the date of the last influenza 
vaccination and the  source of the influenza history (recall or medical source) is to be captured in 
the eCRF. All  subjects who received at least one influenza vaccination within the previous  [ADDRESS_453433] ’s 
medical history are to be recorded on the Concomi tant Medications eCRF.  Receipt of a ny COVID -
19 vaccine at any time prior to enrol lment needs to be recorded on the Concomitant Medications 
eCRF . 
Note that this includes all medications and vaccines described in the inclusion and exclusion  
criteria, includi ng: 
• Immunoglobulins or any blood products within 180 days prior to informed consent ; 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 59 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
• Administration of antineoplastic and immunomodulating agents or radiotherapy  within 90 
days prior to informed consent ; 
• An investigational or non -registered medicinal produ ct within 30 days prior to  informed 
consent ; 
• Systemic administration of corticosteroids (PO/IV/IM) at a dose  equivalent to  ≥20 mg/day 
of prednisone for more than 14 consecutive days within 90 days prior to  informed consent ; 
• Any influenza vaccine within 6 m onths prior to vaccination in this study ; 
• Receipt of any inactivated non -influenza vaccine 14 days or live -attenuated vaccine 28 days 
prior to enrollment in this study or plan to receive any other non -influenza vaccine within 
28 days from study vaccination ; 
• Receipt  of any COVID -19 vaccine within 14 days (non -replicating vaccines) or 28 days 
(replicating vaccines) prior to enrollment or plan to receive any COVID -[ADDRESS_453434] should not be enrolled in the study as per the exclusion criteria.  
The use of antipyretics and/or analgesic medications within [ADDRESS_453435] be 
identified and the reason for th eir use (prophylaxis versus treatment) must be described in the 
source document and Concomitant Medications eCRF.  The prophyla ctic use of  
antipyretics/analgesics within 24 hours prior to vaccine administration is a reason to delay  study 
vaccination (see Section 4.3, Criteria for Delay of Vaccination ). 
Medications taken for prophylaxis are those intended to prevent the onset of symptoms.  
Medications taken for treatment are intended to reduce or eliminate the presence of  symptoms that 
are present.  
Concomitant  medications and vaccines  
Concomitant medications include all medications (including vaccines) taken by/administered to the 
subject after  study vaccination . 
The following concomitant medications  are to  be recorded in the Concomitant Medications  CRF:  
• All concomitant medications from Day 1 to Day 2 2; 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 60 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
• All medications associated with SAEs, AESIs, and AEs that lead to  premature withdrawal 
from the study, from Day 1 to study completion ; 
• All vaccines, including any seasonal /pandemic influenza or COVID -19 vaccines, from Day 
1 to study completion;  
• Any investigational and non -registered medicinal product (other than the study vaccines) 
during the entire study period (from Visit 1 to study completion).  
In addition, the use of the  following concomitant medications, for conditions reported in the 
medical history, from enrolment until end of the study should be documented on the Concomitant 
Medication eCRF page as they may have an effect on the interpretation of the study objectives and 
therefore if used, may be determined to be a reason for exclusion from one of the analysis sets.  
• Blood, blood products or a parenteral immunoglobulin preparation;  
• Oral or systemic corticosteroids;  
• Other immunomodulating agents.  
6.6 Vaccine Supply, Labeling , Storage and Tracking  
The Sponsor will ensure the following:  
– Supply the study vaccines.  
– Appropriate labeling of all study vaccines provided that it complies with the legal 
requirements of each country where the study is to be performed.  
– Appropriate storag e and distribution of study vaccines.  
The investigator must ensure the following:  
– Acknowledge receipt of the study vaccines by a designated staff member at the site, 
including:  
– Confirmation that the vaccines were received in good condition  and in the right amount;  
– Confirmation that the required temperature range during shipment from the Sponsor to the 
investigator ’s designated storage location has been maintained;  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 61 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
– Report any temperature deviation and do not use vaccines until further confir mation by [CONTACT_363990].  
– Proper storage of the study vaccines, including:  
– Storage in a secure, locked, temperature -controlled location ; 
– Proper storage according to the instructions specified on the labels  and in the Investigator 
Pharmacy  Manual;  
– Appropriate record keepi[INVESTIGATOR_299878], including regular 
documentation of adequate storage temperature.  
– Appropriate use of the study vaccines, including:  
– Use only in accordance with the appr oved protocol.  
– Proper handling, including confirmation that the vaccine has not expi[INVESTIGATOR_363938] 
a temperature excursion  prior to administration.  
– Appropriate documentation of administration of vaccines to study subjects including:  
o Date, dosage, b atch/lot numbers, expi[INVESTIGATOR_1659], unique identifying numbers 
assigned to subjects and study vaccines, and time of vaccine administration. This 
information will be maintained in an accountability log that will be reviewed by [CONTACT_363991] ; 
o Reconciliati on of all vaccines received from the Sponsor. Reconciliation is defined 
as maintaining records of which and how many vaccines were received, which 
vaccines were administered to subjects, which vaccines were destroyed at the site, 
and which vaccines were re turned to the Sponsor, as applicable.  
– Proper adherence to the local institutional policy with respect to destruction of study 
vaccines ; 
– Complete record keepi[INVESTIGATOR_29216], wastage, return or destruction, including 
documentation of:  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 62 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
• Copy of the site ’s procedure for destruction of hazardous material . 
• Number of doses destroyed, date of destruction, destruction code (if available), method of 
destruction, and name [CONTACT_364035].  Sponsor approval is required prior 
to destruction of any unused vaccines.  
Vaccines that have been stored differently from the manufacturer ’s indications must not  be used 
unless the Sponsor provides written authorization for use. In the event that the use cannot be 
authorized, the Sponsor will make every effort t o replace the vaccine supply. All vaccines used in 
conjunction with this protocol must be stored separately from normal hospi[INVESTIGATOR_307]/practice stocks to 
prevent unintentional use of study vaccines outside of the clinical study setting.  
Monitoring of vaccine acc ountability will be performed by [CONTACT_363992].  
At the conclusion of the study, and as appropriate during the course of the study, the investigator 
must ensure that all unused study vaccines, packag ing and supplementary labels are destroyed 
locally (upon approval from Sponsor) or returned to the Sponsor.  
[ADDRESS_453436] a causal 
relationship with this treatment ; therefore, an AE can be any unfavorable and unintended sign 
(including an abnormal laboratory finding, for example), symptom, or disease temporally 
associated with the use of an investigational product, whether or not considered related to the 
investigational product.  This definition includes in tercurrent illnesses or injuries and exacerbation 
of pre -existing conditions.  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 63 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453437] has  received 
the study vaccine  until he or she completes the study completion visit  (Day 271 ) or terminates the 
study early. E vents occurring after the informed consent form is signed but prior to receiving study 
vaccine will be documented as medical history  in the source document  and medical history eCRF .  
Adverse events are collected as either solicited or unsolicited AEs. Solicited events are derived 
from organized data collection systems, such as Subject eDiaries or interview.  
 Solicited Adverse Events  
The term “reactogenicity ” refers to solicited signs and symptoms (“solicited adverse events ”) 
occurring in the hours and days following a vaccination, to be collected by [CONTACT_363993] 
[ADDRESS_453438] eDiary  will be continued until 
the event(s) resolved or for a maximum of [ADDRESS_453439] e Diary.  
Injection site pain will be measured as follows: grade 0= absent, grade 1/mild= present  but does not 
interfere with activi ty, grade 2/moderate = interferes with activity, grade  3/severe = prevents daily 
activity.  
Solicited Systemic  Adverse Events  
The following solicited systemic AEs are included in the Subject eDiary. Each solicited systemic 
AE is to be assessed using the sco ring system reported in Table 7-1 below:  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 64 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
Table 7-1: Severity Grading for Solicited Systemic Adverse Events  
Solicited Event  Grade 1/Mild  Grade 2/Moderate  Grade 3/Severe  
Loss of appetite  Eating less than usual 
with no effect on normal 
activity  Eating less than usual 
/interfere s with normal 
activity  Not eating at all  
Nausea  No interference with 
daily activity  Interferes with daily 
activity  Prevents daily activity  
Fatigue  No interference with 
daily activity  Interferes with daily 
activity  Prevents daily activity  
Myalgia  No interference with 
daily activity  Interferes with daily 
activity  Prevents daily activity  
Arthralgia  No interference with 
daily activity  Interferes with dail y 
activity  Prevents daily activity  
Headache  No interference with 
daily activity  Interferes with daily 
activity  Prevents daily activity  
Chills  No interference with 
daily activity  Interferes with daily 
activity  Prevents daily activity  
Vomiting  1-2 times per 24  hours  3-5 times per 24 hours  6 or more  times per 
24 hours  or requires 
intravenous hydration  
Diarrhea  2-3 loose stools per 
24 hours  4-5 loose stools per 
24 hours  6 or more  loose stools  per 
24 hours  or requires 
intravenous hydration  
Fever  38.0 – 38.4°C  
100.4 – 101.1°F  38.5 – 38.9°C  
101.2 – 102.0°F  ≥39.0°C  
≥102.1°F  
Other Indicators of Reactogenicity  
The use of analgesics/antipyretics will be captured as “absent ” or “present ” separately by [CONTACT_48933] 
“for treatment ” or “for prevention ”. 
Note: Any solicited AE that meets any of the following criteria must be entered into subjects ’ 
source document (see Section 9.1, Source Documentation ) and also as an AE on the AE eCRF:  
• Solicited local or systemic AE  leading to the subject withdrawing from the study or the subject 
being withdrawn from the study by [CONTACT_093] (AE leading to withdrawal, see Section 
7.1.3, Evaluation of Adverse Events).  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 65 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
• Solicited local or s ystemic AE that otherwise meets the definition of a n SAE (see Section 7.1.4, 
Serious Adverse Events ). 
 Unsolicited Adverse Events  
An unsolicited AE is an AE that was not solicited using a Subject eDiary and that was 
spontaneously communicated by a subject who was vaccinated . 
Potential unsolicited AEs may be medically attended (defined as symptoms or illnesses requiring 
hospi[INVESTIGATOR_059], or emergency room visit, or visit to/by a qualified healthcare professional ) or were 
of concern to the subject. In case of such events, subjects will be instructed to contact [CONTACT_361716]. The detailed information about the reported unsolicited AEs will be collected by 
[CONTACT_363994] ’s records. In 
this study, all unsolicited AEs will be collected during the treatment period (Day 1 -Day 22), and 
only specific unsolicited AEs (SAEs, AEs leading to withdrawal and AESIs) will be collected  
during the fo llow-up period ( Day 23 -Day 271) . In addition, any unsolicited AEs reported within 
[ADDRESS_453440] 
for an underlying diagnosis and to capture this diagnosis as the event in the AE eCRF . In other 
words, the practice of reporting only symptoms (e.g., “cough ” or “ear pain ”) are better reported 
according to the  underlying cause (e.g., “asthma exacerbation ” or “otitis media ”). 
The severity of events reported on the AE eCRF  will be determined by [CONTACT_1694]:  
Mild:  transient with  no limitation in normal daily activity.  
Moderate:  some limitation in normal da ily activity.  
Severe:  unable to perform normal daily activity.  
The relationship of the study treatment to an AE will be determined by [CONTACT_311874]:  
1. Not Related  
The AE is not related to an investigational vaccine if there is an evidence that clearly indicates an 
alternative explanation.  If the timing of the exposure to the vaccine and the onset of the AE are not 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 66 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453441] an 
alternative explanation, then the AE is not related.  
2. Possibly Related  
The administration of the investigational vaccine and AE are considered reasonably related in time 
and the AE could be explained by [CONTACT_363995].  
3. Probably Related  
Exposure to the investigational vaccine and AE are reasonably related in time and no alternative 
explanation has been identified.  
Adverse events will also be evaluated by [CONTACT_941] i nvestigator for the co -existence of any of the other 
following conditions : 
• Adverse events of special interest  (see Section [IP_ADDRESS], Adverse Events of Special Interest ) 
• Adverse events  leading to study withdrawal.  
 
If solicited or unsolicited AEs have been reported and the subject indicated that the symptoms 
required medical attendance, the subject must be contact[CONTACT_83529].  
When the subject is contact[CONTACT_363996], the contact [CONTACT_363997] ’s source documentation. All AEs to be collected in this study, regardless of severity, will be 
monitored until resolution or until the investigator assesses them as chronic or stable. All subjects 
experiencing AEs - whether considered a ssociated with the use of the study vaccine or not - must 
be monitored until symptoms subside and any abnormal laboratory values have returned to 
baseline, or until there is a satisfactory explanation for the changes observed, or until death, in 
which case  a full pathologist ’s report should be supplied, if possible. The investigator ’s assessment 
of ongoing AEs at the time of each subject ’s last visit should be documented in the subject ’s 
medical chart.  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 67 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
 Serious Adverse Events  
An SAE is defined as any untowar d medical occurrence that at any dose results in one or more of 
the following:  
• Death ; 
• Is life -threatening (ie, the subject was, in the opi[INVESTIGATOR_871], at immediate risk of 
death from the event as it occurred); it does not refer to an event whi ch hypothetically might 
have caused death if it were more severe ; 
• Required or prolonged hospi[INVESTIGATOR_059] ; 
• Persistent or significant disability/incapacity (ie, the event causes a substantial disruption of a 
person’s ability to conduct normal life functions) ; 
• Congenital anomaly/or birth defect ; 
• An important and significant medical event that may not be immediately life -threatening or 
resulting in death or hospi[INVESTIGATOR_313], based upon appropriate medical judgment, may 
jeopardize the subject or may require in tervention to prevent one of the other outcomes listed 
above.  
Adverse events which do not fall into these categories are defined as non -serious . 
It should be noted that a severe AE need not be serious in nature and that a n SAE  need not, by 
[CONTACT_108], be s evere.  
All SAEs will be evaluated by [CONTACT_299934]. The 
SAEs that are judged to be possibly or probably related to the study vaccine should be reported to 
the Sponsor  as related /suspected events.  
The relationship of the study treatment to an SAE will be determined by [CONTACT_363998]:  
1. Related/suspected  
The SAE is judged by [CONTACT_363999] (see Section 7.1.3, Evaluation of Adverse Events).  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 68 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
2. Not Related  
The SAE is not related if the occurrence of the SAE is not reasonably related in time, or the SAE is 
considered unlikely to be related to use of the study  vaccine, i.e., there are no facts (evidence) or 
arguments to suggest a causa l relationship.  
The relationship of the study vaccine  to an SAE will be determined by [CONTACT_093] . 
In addition, SAE s will be evaluated by [CONTACT_364000] “expectedness. ” An unexpected 
AE is one that is not listed in the current Investigator ’s Brochure or an event that is by [CONTACT_364001] a listed event.  
A pre-existing event or con dition should be recorded on the Medical History eCRF . The worsening 
of a pre -existing event or condition should be reported as an AE as described in  Sections 5.1.2, 
Screening and 7.1.2, Unsolicited Adverse Events . Worsening of a pre -existing  event or condition 
should be reported as SAE if meets any of SAE criteria.  If the onset of an event occurred before the 
subject entered the study  (e.g., any pre -planned hospi[INVESTIGATOR_363939] -emergency routine visits for a pre -existing condition), the hospi[INVESTIGATOR_363940], in the view of the investigator, 
hospi[INVESTIGATOR_120513] a result o f participation in the clinical study  or was necessary due 
to a worsening of the pre -existing condition.  
[IP_ADDRESS]  Adverse Events of Special Interest  
Adverse events of special interest (AESIs) are a predefined list of AEs that are immune -mediated 
medical conditions ; the list of AESIs is presented  in APPENDIX 2 – List of Adverse Events of 
Special Interest . 
Subjects will be assessed at each visit for any new medical events or signs or symptoms that could 
possibly indicate an AESI. The subject will be asked whether any new diagnosis has been given to 
the subject through a review of recent medical history. Should a qualified healthcare professional 
who is not the investigator suspect a potential AESI, she/he should promptly inform the 
investigator.  
A dia gnosis of an AESI is to be reported in the same manner and time frame as an SAE and will be 
captured on the AE eCRF. If the eCRF is not available, then the study site must complete the paper 
AESI Report Form and send to Seqirus Pharmacovigilance and Risk M anagement (PVRM) (or 
delegate) at [EMAIL_6961] . The investigator must notify Seqirus within 24 hours. 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 69 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453442] ’s source documents and on the AE eCRF.  
 Methods for Recording Adverse Events and Serious Adverse Events  
Findings regarding AEs must be re ported on an AE eCRF , as specified in Section 7.1.2, Unsolicited 
Adverse Events . All findings in subjects experiencing AEs must be reported also in the subject's 
source document.  
All SAEs which occur during the course of the study, whether considered to be associated with the 
study vaccination or not, must be reported within [ADDRESS_453443] co mpete the paper SAE Report For m and send 
to Seqirus PVRM (or delegate) at [EMAIL_6961]  within 24 hours of the site 
becoming aware of the event . Once the eCRF is available, the SAE information shou ld be 
recorded on the AE eCRF as soon as possible.  
Any medication or other therapeutic measures used to treat the AE will be recorded on the 
appropriate eCRF (s) in addit ion to the outcome of the AE.  
After receipt of the initial report, representatives of Seqirus (or delegate) will contact [CONTACT_364002].  
All SAEs  must be reported by [CONTACT_299940]/her corresponding  EC/IRB or applicable 
regulatory authorities  in accordance with institutional policy/regulatory requirements and adequate 
documentation of this notification must be provided to the Sponsor.  
Seqirus  or its designee must also comply with the applicable regulatory requirement(s) related to 
the reporting of  suspected unexpected serious adverse reactions (also known as S[LOCATION_003]Rs) to the 
regulatory authority(ies) and the IRB/EC. If a S[LOCATION_003]R or other safety signal relating to use of one 
of the study vaccines is reported to Seqirus  or its designee, the Sponsor will communicate the 
information to the investigator and the investigator will be responsible for submitting this 
information to the EC/IRB or applicable regulatory authorities  and other relevant authorities.  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 70 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
[IP_ADDRESS]  Post-Study Events  
Any SAE that occurs outside of the  protocol -specified observation period or after the end of the 
study but is considered to be caused by [CONTACT_364003] (or 
delegate) and must be reported at AE.reporting@se qirus.com . 
These SAEs will be considered as part of the spontaneous reporting towards the investigational 
study vaccine in order to ensure the safety of all subjects.  
 Pregnancies  
If a subject becomes pregnant after vaccination, confirmation of pregnancy should be recorded in 
the eCRF. To ensure subjects ’ safety, each pregnancy in a subject after study vaccination must be 
reported to Seqirus PVRM ( or delegate ) within [ADDRESS_453444] complete the paper Pregnancy Reporting/Outcome Form and send it to  
[EMAIL_6961] . If the subject agrees to submit this information, the preg nancy must be 
followed to determine the outcome, including spontaneous or voluntary termination, details of the 
birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or 
newborn complications. This follow -up shou ld occur even if the intended duration of safety follow -
up for the study has ended.  
 Safety Laboratory Measurements  
No scheduled safety laboratory measurements are planned for this study.  
7.[ADDRESS_453445], i.e., widely used and generally 
recognized as reliable, accurate, and relevant (able to describe the quality and extent of the immune 
response).  
The immunogenicity analysis will evaluate the immunogenicity of the study vaccine s, which  will 
be measured by [CONTACT_364004].  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 71 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
For the primary and secondary immunogenicity objectives, HI antibody responses using a n egg -
derived target  virus will be evaluated for all strains  included in the study vaccines . In case of a lack 
of agglutination or agglutination mediated through neuraminidase  for a specific strain  using HI 
assay, immunogenicity for that strain will be ass essed as measured by [CONTACT_364005].  
For the exploratory  objective of persistence of the immune response at  9 months after vaccination , 
HI antibody responses for all strains  included in the study vaccines  will be evaluated  using a n egg -
derived target  virus at a later stage . For this analysis,  Day 1 serum samples obtained for the primary 
and secondary study objectives (noninferiority and superiority assessments ) will be retested. Day [ADDRESS_453446] heterologous strains or alternative assay methods (e.g., 
MN) .  
Additionally, sera samples may be tested in future research not directly related to this study, but 
with the purpose to improve the understanding of the influenza vaccines or disease . 
Testing will be conducted by [CONTACT_364006] a blinded manner  with respect 
to the treatment arm  and the visit . 
8 STATISTICAL CONSIDERATIONS  
8.1 Endpoints  
A complete description of the statistical analyses and methods will be available in the Statistical 
Analysis Plan (SAP), which will be drafted before the first subject is enrolled and finalized before 
the database is locked for the primary analysis. The primary analysis will be conducted on the 
immunogenicity  data collected up to Day 22.  
 Primary Endpoints  
The immunogenicity of the study vaccines will be assessed 21 days (ie, on Day 22) after vaccine 
administration by [CONTACT_364007] A/H1N1, A/H3N2, B/Yamagata , and 
B/Victoria strains included in the vaccines.  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 72 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
[IP_ADDRESS]  Primary Efficacy Endpoint(s)  
The study does not have a primary clinical efficacy endpoint.  
[IP_ADDRESS]  Primary Immunogenicity Endpoint(s)  
Humoral immune response s in terms of HI13 antibody response against homologous egg-derived  
vaccine strains (A/H1N1, A/H2N3, B/Yamagata , and B/Victoria):  
• Geometric mean titer (GMT) of HI antibodies at Day 22 ; 
• Seroconversion rate (SCR) defined as the percentage of subject s with either a 
prevaccination HI titer <1:10 and a postvaccination (Day 22) HI titer ≥1:40, or with either a 
prevaccination HI titer ≥1:10 and a ≥4-fold increase in postva ccination HI titer.  
The derived variables are:  
• GMT ratios ( QIV/aQIV) at Day 22 for each strain ; 
• The inter-group differences in the SCRs ( QIV - aQIV) at Day 22 for each strain.  
To evaluate the primary immunogenicity objectives 1a and 1b, the following derived variables of 
GMT ratios and SCR differences will be assessed  at Day 22 : 
1a. Noninferiority of aQIV compared to QIV will be assessed for the eight primary endpoints of HI 
GMT and SCR for each virus strain included in the vacci nes as follows:  
• The GMT ratio  (QIV/aQIV)  for the A/H1N1 strain;  
• The GMT ratio (QIV/aQIV) for the A/H3N2 strain;  
• The GMT ratio (QIV/aQIV) for the B strain (Yamagata lineage);  
• The GMT ratio (QIV/aQIV) for the B strain (Victoria lineage);  
                                                 
13 In case of lack of agglutination or agglutination mediated through neuraminidase for a specific strain using HI assay, 
immunogenicity for that strain will be assessed as measured by [CONTACT_363947] (MN ) assay as an acceptable alternative.  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 73 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
• The difference betwe en the SCR (QIV-aQIV)  for the A/H1N1 strain;  
• The difference between the SCR (QIV-aQIV) for the A/H3N2 strain;  
• The difference between the SCR (QIV-aQIV) for the B strain (Yamagata lineage);  
• The difference between the SCR (QIV-aQIV) for the B strain (Victori a lineage).  
1b. A superior immune response of aQIV compared to QIV will be assessed for the endpoints of HI 
GMT for each virus strain included in the vaccines as follows:  
• The GMT ratio (QIV/aQIV) for the A/H1N1 strain;  
• The GMT ratio (QIV/aQIV) for the A/H3N2 strain;  
• The GMT ratio (QIV/aQIV) for the B strain (Yamagata lineage);  
• The GMT ratio (QIV/aQIV) for the B strain (Victoria lineage);  
[IP_ADDRESS]  Primary Safety Endpoint(s)  
The study does not have a primary safety endpoint . 
 Secondary Endpoint(s)  
Secondary endpoints assessed in the study include immunogenicity and safety endpoints of solicited 
and unsolicited AEs. 
[IP_ADDRESS]  Secondary Safety Endpoint(s)  
Safety and reactogenicity will be assessed by [CONTACT_12218]:  
• Solicited local and systemic A Es for 7 days following vaccination (Day 1 through Day 7);  
• All unsolicited AEs for 21 days following vaccination (Day 1 through Day 22);  
• SAEs, AEs leading to withdrawal from the study, AESIs as collected from Day 1 through 
Day 271.  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 74 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
[IP_ADDRESS]  Secondary Efficacy Endpo int(s)  
The study does not have a second ary clinical efficacy endpoint.  
[IP_ADDRESS]  Secondary  Immunogenicity Endpoint(s)  
Humoral immune response in terms of HI antibody response against homologous egg-derived  
vaccine strains (A/H1N1, A/H2N3, B/Yamagata , and B/Victoria):  
• GMT of HI antibodies at Day 22  and Day 181 . 
To evaluate the second ary immunogenicity objectives 2a and 2b, the following derived variables of 
GMT ratios will be assessed:  
2a. Superior immune response of aQIV compared to QIV will be assess ed for HI GMT for the 
strain s included in the vaccines as follows:  
• The GMT ratio (QIV/aQIV) at Day 22.  
2b. Greater persistence of the immune response of aQIV compared to QIV will be assessed for HI 
GMT for the strain s included in the vaccines as follows:  
• The GMT ratio (QIV/aQIV) at Day 181 . 
2c. To evaluate the immunogenicity of aQIV compared with QIV as measured by [CONTACT_363958] 50 -
64 years of age  as follows:  
• GMT of HI antibodies on Day 1, Day 22  and Day 181.  
• Geometric mean fold increase (GMFI): The geometric mean of the fold increase of 
postvaccination HI titer over the prevaccination HI titer (Day 22/Day 1, Day 181/Day 1) . 
• The percentage of subjects with a titer ≥1:40 at Day 1, Day 22, and Day 181 . 
• SCR: the percentage of subjects with either a preva ccination HI titer <1:10 and a 
postvaccination HI titer ≥1:40 or a prevaccination titer ≥1:10 and a ≥4-fold increase in 
postvaccination titer on Day 22, and Day 181.  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 75 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
 Exploratory  Endpoint (s) 
[IP_ADDRESS]  Exploratory Safety Endpoint(s)  
Not applicable.  
[IP_ADDRESS]  Exploratory Efficac y Endpoint(s)  
Not applicable.  
[IP_ADDRESS]  Exploratory Immunogenicity Endpoint(s)  
Persistence of the immune response of aQIV compared to QIV at Day 271 will be assessed for HI 
GMT for all strains included in the vaccines through the same descriptive immune response 
parameters as presented for secondary objective 2c, and  further explored through the GMT ratio 
(QIV/aQIV) . For this analysis,  Day 1 serum samples obtained for the primary and secondary study 
objectives (noninferiority and superiority assessments ) will be retested. Day [ADDRESS_453447] 
homologous  or heterologous  strains at Day 1 , Day 22 , Day 181 , and Day 271 (depending on 
availability of  adequate sera and on assay availability). Details will be  described in the SAP. 
8.2 Success Criteria  
 Success Criteria for Primary Objective(s)  
[IP_ADDRESS]  Success Criteria for Primary Safety Objective(s)  
The study does not have primary safety objectives . 
[IP_ADDRESS]  Success Criteria for Primary Efficacy Objective(s)  
The study does not have  primary efficacy objectives.  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 76 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
[IP_ADDRESS]  Success Criteria for Primary Immunogenicity Objective(s)  
Succes s criterion for primary immunogenicity objective 1a is defined as:   
Noninferiority of the aQIV immune response  will be demonstrated if the UL of the 95% CI for  the 
inter-group Day 22 GMT ratio ( QIV/aQIV) is ≤1.5 for each vaccine strain, and the UL of the 95% 
CI for the difference in SCR ( QIV - aQIV) is ≤10% for each vaccine strain.  
Succes s criterion for primary immunogenicity objective 1b is defined as:   
Superiority of the aQIV immune response will be demonstrated if the UL of the 95% CI for the 
inter-group Day 22 GMT ratio ( QIV/aQIV)  is <1.[ADDRESS_453448] ive 1a is achieved.  
 Success Criteria for Secondary Objective(s)  
[IP_ADDRESS]  Success Criteria for Secondary Safety Objective(s)  
No success criteria  for secondary safety objectives are prespecified . 
[IP_ADDRESS]  Success Criteria for Secondary Efficacy Objective(s)  
The study does not have second ary efficacy objectives.  
[IP_ADDRESS]  Success Criteria for Secondary Immunogenicity Objective(s)  
Succes s criterion for secondary immunogenicity objective 2a is defined as :  
Superior immune response will be demonstrated if the UL of the 98.73% CI for  the inter-group 
GMT rat io (QIV/aQIV)  is <0.67 for one or more vaccine  strain s. 
Succes s criterion for secondary immunogenicity objective 2b is defined as :  
Greater persistence of the immune response will be demonstrated if the UL of the 98.73% CI for  
the inter-group GMT ratio (QIV/aQIV) <1.0 for one or more vaccine  strain s at 6 months .  
For secondary immunogenicity objective 2c, no success criteria are prespecified ; 95% CI bounds 
will be used for statistical descriptions . 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 77 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453449] ID,  and provide 
demographic and/or baseline screening assessments, regardless of the subject ’s randomization and 
treatment status in the study . 
 All Exposed Set  
All subjects in the  All Enrolled Set who receive a study vaccination.  
 Safety Set  
Subjects will be analyzed “as treated ” (i.e., according to the vaccine a subject received, rather than 
the vaccine to which the subject may have been randomized).  
Solicited Safety Set  
All subjects in the All Exposed Set with any solicited AE data including temperature measurements 
or use of analgesics/antipyretics . 
Unsolicited Safety Set  
All subjects in the Exposed Set who provided  unsolicited AE data.  
Overall Safety Set  
All subjects who are in the Solicited Safety Set and/or Unsolicited Safety Set.  
 Full Analysis Set (FAS) Immunogenicity  
Full Analysis Set Immunogenicity  
All subjects in the All Enrolled Set who are randomized, receive d study  vaccination and provide 
immunogenicity data a t any time po int. 
In case of vaccination error, subjects in the FAS sets will be analyzed “as randomize d” (i.e., 
according to the vaccine the subject  was designated  to receive , which may be different from the 
vaccine the subject  actually received).  
The FAS  Immunogenicity will be used for immunogenicity superiority comparisons.  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 78 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
 Per Protocol Set (PPS) Immunogenicity  
All subjects in the FAS Immunogenicity  who:  
• Have both Day 1 and Day 22 immunogenicity assessment.  
• Correctly receive the vaccine (i.e., receive the vaccine to which the subjects are randomized and 
at the scheduled time points).  
• Have no protocol deviations leading to exclusion ( see Section 8.3.8, Protocol Deviati ons) as 
defined prior to unblinding / analysis.  
• Are not excluded due to other reasons defined prior to unblinding or analysis (see Section 8.3.8, 
Protocol Deviations ) 
The PPS Immunogenicity will be used for  immunog enicity  noninferiority comparisons.   
 Other Analysis Set(s)  
Not applicable.  
 Subgroup(s)  
Primary and secondary analyses of immunogenicity and safety endpoints will be done for the  total 
population and by [CONTACT_56328]  (50-59 and 60 -64 years of age).  
Additional subgroup analysis will be conducted by: 
• previous vaccination history  
• sex 
• race 
• ethnicity  
• comorbidity risk score (<50 and ≥50) 
Refer to the SAP for further details.  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 79 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
 Protocol Deviation(s)  
A protocol deviation is any change, divergence, or departure  from the study design or procedures of 
a study protocol. A protocol deviation may be a reason to remove data from an analysis set at the 
time of analysis. CSR -reportable protocol deviations will be defined as exclusionary from the 
analysis according to pr otocol objectives and endpoints, which will be specified in the SAP. In 
some cases,  exclusion of data may be due to a reason other than a protocol dev iation, e.g. early 
termination.  
8.4 Statistical Analysis Plan  
 Analysis of Demographic and Baseline Characteris tics 
Descriptive statistics (mean, standard deviation, median, minimum , and maximum) for age, height , 
weight , body mass index , and comorbidity risk score at enrol lment will be calculated overall and by 
[CONTACT_2948].  
Distributions of subjects by [CONTACT_4321], age, ethnic origin (race, ethnicity), previous vaccination history , 
and comorbidity risk (low/high defined as assessment score <50 or ≥50 based on scale described in 
Section 5.1.2, Screening ) will be summarized overall, by [CONTACT_2948], and by [CONTACT_551].  
 Analys is of Primary Objective(s)  
[IP_ADDRESS]  Analysis of Primary Safety Objective(s)  
The study does not have primary safety objectives.  
[IP_ADDRESS]  Analysis of Primary Efficacy Objective(s)  
The study does not have primary efficacy objectives.  
[IP_ADDRESS]  Analysis of Primary Immunogenicity Objective(s)  
The primary immunogenicity objectives are:  
1a. To demonstrate immunological noninferiority of aQIV versus QIV in subjects 50 -64 years 
of age, as measured by [CONTACT_35318] (HI) geometric mean titers (GMTs) and 
seroconversion rates (SCR s) for each vaccine strain, at 3 weeks after vaccination.  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 80 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453450] 2 of the 4 
vaccine strain s. 
[IP_ADDRESS].1  Statistical Hypothesis  
Noninferiority of aQIV to QIV (Objective 1a)  
To demonstrate that vaccination with aQIV e licits an immune response th at is not inferior to that of 
QIV containing the same virus strains amon g adults 50-64 years of age , aQIV will be considered to 
be noninferio r to QIV if, for each of the four strains, the following statistical criteria are met:  
• The UL of the two -sided 95% CI for the ratio of the Day 22 GMTs (GMTr) does not exceed 
1.5. The GMTr  will be calculated by [CONTACT_364008]/GMT aQIV  
• The UL of the two -sided 95% CI for the difference between the SCRs does not exceed 10%. 
The difference in SCR will be  calculated by [CONTACT_364009] – SCR aQIV  
The statistical hypotheses to be tested for the primary immunogenicity objective  1a correspond to:  
H0: GMTri >1.5, for any strain  
Ha: GMTri  ≤1.5, for all strain s  
and  
H0: Di >10%, for any strain  
Ha: Di ≤10%, for all strain s  
where GMTri  (i=1,2,3,4) is any of the 4 strain -specific Day 22  GMT ratios , namely,  
• GMTr 1=GMT QIV/GMT aQIV for A/H1N1 strain  
• GMTr 2=GMT QIV/GMT aQIV for A/H3N2 strain  
• GMTr 3=GMT QIV/GMT aQIV for B/ Yamagata  strain  
• GMTr 4=GMT QIV/GMT aQIV for B/ Victoria  strain  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 81 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
and Di (i=1,2,3,4) is the 4 strain -specific Day 22  SCR  differences  (πQIV,i-πaQIV ,i), namely,  
• D1=πQIV,1 – πaQIV ,1 for A/H1N1 strain  
• D2=πQIV,2 – πaQIV ,2 for A/H3N2 strain  
• D3= πQIV,3 – πaQIV ,3 for B/ Yamagata  strain  
• D4= πQIV,4 – πaQIV ,4 for B/ Victoria  strain  
where πQIV,i, πaQIV ,i (i=1,2,3,4) denotes t he SCRs  for the 4 strains in QIV and aQIV respectively . 
Superiority  of aQIV to QIV (Objective 1b)  
To demonstrate that aQIV induces a superior immune  response compared to QIV in subjects [ADDRESS_453451] 2 of the 4 vaccine 
strain s, aQIV will be considered to be superior to QIV if the following statistical criteria are met:  
The UL of the 95% CI for the inter-group GMT ratio ( QIV/aQIV)  is <1.[ADDRESS_453452] 2 of the 4  
vaccine strain s. 
The statistical hypotheses to be tested for the primary immunogenicity objective 1b  correspond to:  
H0: GMTri ≥1, for at least 3 of the 4 vaccine strains at Day 22     
Ha: GMTri  <1, for at least 2 of the 4 vaccine  strain s at Day 22  
where GMTri  (i=1,2,3,4) are defined as above.  
[IP_ADDRESS].2  Analysis Sets  
The PPS Immunogenicity will be used for the primary immunogenicity noninferiority analysis  1a, 
and a supporting analysis will be performed using the FAS Immunogenicity . The FAS 
Immunogenicity will be used for the primary immunogenicity superiority analysis  1b, and a 
supporting analysis will be performed using the PPS Immunogenicity.  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 82 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
[IP_ADDRESS].3  Statistical Methods  
All statistical analyses for HI (or MN  if applicable ) titers will be performed on the logarithmically 
(base 10) transformed values. Individual HI titers below the detection limit (<10) will be set to half 
of that limit (5 ); values above the upper l imit of quantification will be set to the upper limit.  
Reverse cumulative distribution curves will be derived by [CONTACT_5586] -point and strain.  
Crude estimates for GMTs, GMFI s, and pertaining 2 -sided 95% CIs will be calculated assuming a 
log-normal distribution of  the titers and will be completed by [CONTACT_364010], maximum and 
median titers for each treatment  group. Binary data (i.e., percentages of subjects with 
seroconversion and with titer ≥1:40) will be summarized for each group using crude estimates and 
will be reported together with 2 -sided 95% CIs calculated according to Clopper ’s and Pearson ’s 
method (Clopper and Pearson 1934 ). No multiplicity adjustment to the CI levels will be 
implemented.  
The analysis model for the HI  GMT will us e a general linear model on log -transformed (base 10) 
Day 22  titers as the outcome variable and as covariates: treatment groups (aQIV , and QIV), 
prevaccination titer  (log 10 transformed) , age stratum, gender , and history of any influenza 
vaccina tion within the [ADDRESS_453453] square means (on the log 10 scale) will be produced with 95% confidence limits for QIV versus 
aQIV. The estimated difference and the confidence limits will be back -transformed to obtain 
adjusted GMT ratio s with 95% confidence limits. The adjusted GMT ratio will be the result for 
which the assessment  of the HI GMT primary endpoint will be based on. Each of the 4 strains will 
be analyzed separately.  
Potential cova riate interaction effects will also be examined in the fit of the GLM , as well as the 
other co -variates such as age taken as a continuous factor.  
The differences of binary endpoints (i.e. seroconversion or titer ≥1:40) will be compared using the 
Miettinen and Nurminen method  (Miettinen and Nurminen 1985 ). Additional supportive analyses 
might be done using  generalized linear models with factors for treatment  group, age subgroup, 
prevaccination titer  (log 10 transformed)  as well as vaccination history. Adjusted differences between 
treatment  groups with 2 -sided 95% CI will be calculated based on the model and potential 
interaction effects will be examined.  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 83 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453454] ed 
sequentially according to  the order of the objectives.  Details of the hypothesis testing procedure 
will be specified in the SAP.  
Handling of missing values for immunogenicity data: 
For immunogenicity data, it may be reasonable to consider missing immunogenicity  values as 
missing c ompletely at random (MCAR), i.e. not informative. Therefore, the immunogenicity 
analysis will comprise a complete case analysis only, without introducing any bias. Imputation 
methods will not be used.   
Further details of the statistical methods will be provided in the SAP.  
 Analysis of Secondary Objective(s)  
[IP_ADDRESS]  Analysis of Secondary Safety Objective(s)  
[IP_ADDRESS].1  Analysis of Extent of Exposure  
The number of subjects vaccinated will be presented by [CONTACT_2948].  
[IP_ADDRESS].[ADDRESS_453455] eDiary  will be 
continued until the event(s) resolved or for a maximum of 14 days after vaccination . If the reaction 
continues to be present after Day 14, the event and follow -up is to be captured as an unsolicited AE 
in the eCRF.  A solicited AE will be defined as “present ” or at least mild on any of the recorded  days 
to be counted. This will be summarized as total and for local, systemic and the category  of other  
indicators of reactogenicity  separately. The same tables will be created at each time  point.  
Frequencies and percentages of subjects experiencing each AE will be presented overall and for 
each maximum symptom severity and by [CONTACT_2948]. Postvaccination solicited AEs reported 
from Day 1 to Day 7 will also be summarized for the intervals Day 1 -3 and Day 4 -7 overall and for 
each maximal severity and by [CONTACT_2948].  Injection -site erythema, ecchymosis and induration 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 84 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
will be summarized according to categories based on linear measurements. Please refer to the SAP 
for definitions of categories.  
Each solicited local and systemic AE will also be further su mmarized as “Present ” versus “Absent ”. 
“Present ” will include measurements with a diameter of at least 25 mm.  
The use of antipyretics and analgesics will be summarized by [CONTACT_364011] (prophylactic versus 
treatment) as the number and percentage of subjects reporting use.  
Body temperature will be summarized by 0.5°C increments from 36.0°C up to ≥40°C. 
[IP_ADDRESS].3  Analysis of Unsolicited Adverse Events  
This analysis applies to all AEs occurring during the study, judged either as probably related, 
possibly related, or not related to vaccination  by [CONTACT_093], recorded in the AE eCRF, with a 
start date on or after the date of vaccination. The original verbatim terms used by [CONTACT_364012]. The 
AEs will then be grouped by [CONTACT_364013] (SOC).  
All reported AEs, as well as AEs judged by [CONTACT_364014], will be summarized acco rding to SOC and preferred term within SOC. These summaries 
will be presented by [CONTACT_364015]. When an AE occurs 
more than once for a subject, the maximal severity and strongest relationship to the treatment  group 
will be counted.  
Separate summaries will be produced for the following categories:  
• Unsolicited AEs during the 30 minutes postvaccination;  
• AEs 
• SAEs;  
• Unsolicited AEs that are possibly or probably related to vaccine;  
• AESIs;  
• AEs leading to withdrawal.  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 85 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453456]. In addition, AEs in the categories above will be 
provided as listed data.  
No imputation of missing unsolicited AEs will be used.  
[IP_ADDRESS].4  Statistical Hypotheses  
No statistical hy potheses will be tested.  
[IP_ADDRESS].5  Analysis Sets  
The Solicited Safety Set for the solicited AEs and the Unsolicited Safety Set for all unsolicited AEs. 
[IP_ADDRESS].6  Statistical Methods  
Only descriptive statistics will be calculated and presented.  
[IP_ADDRESS]  Analysis of Secondary Efficacy Objective(s)  
Not applicable  
[IP_ADDRESS].1  Statistical Hypotheses  
Not applicable.  
[IP_ADDRESS].2  Analysis Sets  
Not applicable.  
[IP_ADDRESS].3  Statistical Methods  
Not applicable.  
[IP_ADDRESS]  Analysis of Secondary Immunogenicity Objective(s)  
[IP_ADDRESS].1  Statistical Hypotheses  
Superiority of aQIV vs QIV (higher threshold) (Objective 2a) 
To demonstrate that aQIV induces a superior immune  response compared to QIV in subjects [ADDRESS_453457] one of the vaccine  strain s at 3 weeks after 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 86 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453458] one of  the vaccine strain s 
at Day 22 , the following statistical criteria are met:  
• Superior immune response will be demonstrated if the UL of the 98.73% CI for  the inter-
group GMT ratio ( QIV/aQIV)  is <0.67 for one or more vaccine  strain s. 
The statistical hypotheses to be tested for the second ary immunogenicity 2a correspond to:  
• H0: GMTr ≥0.67, for all four vaccine strains  at Day 22  
• Ha: GMTr  <0.67, for one or more  vaccine strains  at Day 22  
where GMTr  is the Day 22  GMT ratios of GMT QIV/GMT aQIV for that vaccine  strain . 
 
Persistenc e of immune response of aQIV compared to QIV  (Objective 2 b) 
To demonstrate greater persistence of the immune response for at least one of the vaccine  strain s 
at 6 months after vaccination  with aQIV compared with  QIV as measured by [CONTACT_364016] 
50-64 years of age , the statistical hypotheses to be tested for the second ary immunogenicity 2b 
correspond to:  
H0: GMTr ≥1, for all four  vaccine strains  at Day 181  
Ha: GMTr  <1, for one or more vaccine strains  at Day 181  
where GMTr  is 6-month GMT ratio of GMT QIV/GMT aQIV for that strain.  
Greater persistence of the immune response will be demonstrated if the UL of the two -sided 98.7 3% 
CI for inter -group GMT ratio (QIV/aQIV) <1.0 for one or more vaccine strains.  
[IP_ADDRESS].2  Analysis Sets  
The FAS Immunogenicity will be used for the secondary endpoint analyses.  The PPS 
Immunogenicity will be used for supporting  analyses.  
[IP_ADDRESS].3  Statistical Methods  
The statistical analysis method s are the same as the primary immunogenicity analysis  for GMT 
ratio analysis.  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 87 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
 Analysis of Other  Objective(s)  
Not applicable.  
[IP_ADDRESS]  Analysis of Other  Safety Objective(s)  
Not applicable.  
[IP_ADDRESS]  Analysis of Other Efficacy Objective(s)  
Not applicable.  
[IP_ADDRESS]  Analysis of Other  Immunogenicity Objective(s)  
The analysis of the exploratory objectives will be described in full detail in the SAP. 
8.[ADDRESS_453459] QIV. The randomization ratio is 1:1 (aQIV: QIV). The study is designed 
to have  at least 90% power to achieve the primary objectives: to demonstrate the noninferiority of 
GMT and SCR of  aQIV vs QIV for all 4 strain s, and the superiority (superiority margin of 1) of 
GMT of  aQIV vs QIV for at least 2 of the 4  strain s with one-sided significance level α=0.025 . 
The results of a previous clinical study with aTIV and TIV vaccine in subjects 50 -64 years of age 
(Study V7P38) was used to generate assumptions for vaccine effect and sample size.  
It is assumed that the differences  of log 10(GMT) of A/H1N1 is 0.07, with standard deviation of 0.[ADDRESS_453460] 90% of power to demonstrate 
a superiority of aQIV vs QIV for the A/H1N1 strain. The table below shows the po wer of each 
comparison  based on GMT ratio and SCR data from Study V7P38 : 
Strain  Log 10(GMT) 
Differences 
(SD)  Sample Size ( Evaluable  
Subjects ) for 90% Power  Power with 
Sample size of 
2,018 for 
superiority 
(GMTr margin 
of 1) (1,[ADDRESS_453461] s) Power with Sample size 
of 2,018 for NI (Margin 
of 0.67) 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 88 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
A/H1N1  0.07 (0.46)  2,018 (1,816 evaluable 
subjects ) 90% ~100%  
A/H3N2  0.26 (0.61)  260 (234 evaluable  
subjects ) ~100%  ~100%  
B 0.14 (0.48)  552 (496 evaluable  
subjects ) ~100%  ~100%  
 
Strain  SCR  in 
aQIV group  SCR in Comparator group  Power with Sample size of 2 ,018 (1,816 
evaluables) for NI (margin -10%)  
A/H1N1  86% 76% ~100%  
A/H3N2  87% 77% ~100%  
B 82% 80% ~100%  
Abbreviations: aQIV = adjuvanted Quadrivalent Influenza Vaccine; GMT = geometric mean titer; NI =  noninferiority; 
SCR = seroconversion rate ; SD = standard deviation.  
 
Thus w ith 1:1 randomization, 1,816 evaluable subjects  will provide an overall power of 90%  to 
demonstrate the primary objectives of noninferiority and superiority of aQIV vs QIV with one -
sided alpha=0.025 . Assuming a 10% drop out  rate, the total sample size for the study needed is 
2,018  subjects . 
Further details of the sample size calculation will be fully described in the  SAP.  
Hypothesis testing will be carried out by 1a) and 1b) sequentially. Only after the noninferiority  
objectives are achieved, the superiority objectives will be tested. Only after the primary objectives 
are reached, secondary objective will be tested sequenti ally. All primary endpoint analys es will be  
carried out with a one -sided alpha of 0.025 for each comparison. No adjustment for multiple 
endpoints for the primary objectives is necessary . 
8.6 Interim Analysis  
No interim analysis is planned for this study.  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 89 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
9 SOURC E DOCUMENTATION, STU DY MONITORING AND AU DITING  
In order to ensure consistency across sites, study  monitoring and auditing will be standardized and 
performed in accordance with the Sponsor ’s or delegated contract research organization ’s (CRO) 
SOPs and applicable regulatory requirements (e.g., FDA, EMA, and ICH guidelines).  
Prior to enrol lment of the first study subject, Seqirus or delegate will train investigators and/or their 
study staff on the study protocol, all applicable study procedures, documenta tion practices , and all 
electronic systems. eCRF s supplied by [CONTACT_364017]  
(see Section 8.3.1, All Enrolled Set  for definition of enrolled subject). Documentation of screened 
but not enrolled subjects must be maintained at the site and made available for review by [CONTACT_162071]. Data and documents will be checked by [CONTACT_1052]/or monitor.  
9.[ADDRESS_453462] will be instructed  on 
what documents will be required for review as source documents. The kinds of documents that will 
serve as source documents will  be agreed between Sponsor or delegate and investigator and 
designees and  specified in  the Source Document Agreement  (SDA prior to subject enrol lment.  
In addition, source documentation must  include  all of the following: subject identificatio n (on each 
page), eligibility and participation, proper informed consent procedures, dates of visits, adherence 
to protocol procedures, adequate reporting and follow -up of AEs, documentation of 
prior/concomitant medication/vaccines, study vaccine receipt/dispensing/return r ecords, study 
vaccine administration information, any data collected by a telephone conversation with the subject 
and date of completion and reason.  
The subject  must also allow access to the subject ’s medical records. Each subject  must be informed 
of this prior to the start of the study and consent for access to medical records may be required in 
accordance with local regulations.  
All safety data reported by [CONTACT_364018] s. If there ar e multiple sources of information (e.g., Subject eDiary, verbal report of 
the subject, telephone contact [CONTACT_8972], medical chart) supporting the diagnosis of an AE, these 
sources must be identified in the source documents, discrepancies between sources clar ified, the 
ultimate diagnosis must be justified and written in the source documents, and this diagnosis must be 
captured on the AE eCRF . 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 90 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453463]  eDiary data cannot be integrated into  electronic data capture  
(EDC ), each investigator will be provided with a certified archive copy of all diary data relating to 
subjects at that site and must confirm it is readable.  
9.[ADDRESS_453464], Seqirus  or its designee (e.g., a CRO) will develop a 
Clinical Monitoring Plan to specify how centralized and/or on -site monitoring, including clinical 
specimen reconciliation, will be performed for the study. Study progress will be monitored by 
[CONTACT_364019] y to ensure  that: 
• the rights and well -being of  human subjects are protected , 
• the reported study data are accurate, complete, and verifiable from the source documents , and 
• the conduct of the study is in compliance with the current approved protocol/amendmen t(s), 
Good Clinical Practice ( GCP ), and applicable regulatory requirements . 
Contact [CONTACT_364020]. Study data recorded on eCRF s will be verified by [CONTACT_364021] e eCRF  entries 
against source documents in order to ensure data completeness and  accuracy  as required by [CONTACT_364022] (e.g. when an electronic Diary is 
being used by [CONTACT_423].  
Data verification may also be performed through a centralized review of data (e.g., checking for 
outliers or other anomalies).  Additional documents such as the investigator site file, pharmacy 
records, and informed consent  documentation must also be available for review if requested. 
Arrangements for monitoring visits will be made in advance in accordance with the monitoring 
plan, except in case of emergency.  
The investigator and/or site staff must make source documents of subjects enrolled in this study 
available for inspec tion by [CONTACT_364023], when applicable . These documents must also be available for inspection, 
verification and copying, as required by [CONTACT_19124], by [CONTACT_364024] 
(e.g., FDA, EM A and others) and/or ECs/IRBs. The investigator and study site staff must comply 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 91 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
with applicable privacy, data protection and medical confidentiality laws for use and disclosure of 
information related to the study and enrolled subjects.  
Remote Source Data Verification (SDV) may also be performed if allowed by [CONTACT_364025]. The process of remote SDV will be detailed in study specific documents (eg, 
Monitoring Plan) and must be conducted in full compliance with the appli cable regulations, 
sponsor and CRO processes, ensuring the protections of the subject ’s data confidentiality.  
10 DATA MANAGEMENT  
10.1 Data Entry and Management  
In this study, all clinical data (including, but not limited to, AE s/SAEs, concomitant medications, 
medical history, and physical assessments), safety data, and immunogenicity data will be entered 
onto eCRF s in a timely fashion by [CONTACT_1755]/or the investigator ’s dedicated site staff. 
Data entered onto eCRF s are stored on a secure website. The dat a collected on this secure website 
are assimilated into an EDC  system, which is compliant with Title 21 Part 11 policies of the Code 
of Federal Regulations  (FDA 1997 ). The data system includes password protection and inte rnal 
quality checks. The EDC system will be designed and validated by [CONTACT_364026]. The investigator or designated delegate must review data entered and 
electronically sign the eCRF s to verify their accuracy.  
Acce ss to the EDC system for data entry or review will require training and distinct individual 
access code assignments to those site staff members who will be entering study data and those 
involved in study oversight who may review study data. Data are collec ted within the EDC system, 
to which the Sponsor and site monitors have exclusively “read only ” access.  
10.[ADDRESS_453465] confirm and endorse the changes . 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 92 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
10.3 Data Protection  
Seqirus respects the subjects ’ rights to privacy and will ensure the confident iality of their medical 
information in accordance with all applicable laws and regulations.  
The Sponsor as Data Controller according to the General Data Protection Regulation (“GDPR ”) on 
the protection of individuals with regard to the processing of person al data and on the free 
movement of such data  confirms herewith compliance to GDPR in all stages of Data Management.  
[ADDRESS_453466]. These documents 
should be retained for a longer period however if required by [CONTACT_3605](s) or if needed by [CONTACT_456] ( ICH E6  (R2)). 
“Essential documents ” are defined as documents that individually and collectively permit 
evaluation of the conduct of a study and the quality of the data produced. These documents should 
be retained for a longer period, however, if required by [CONTACT_364027]. ( ICH E6 (R2) ). 
The sponsor should inform the investigator(s)/institution(s) in writing of the need for record 
retention and should notify the investigator(s)/instituti on(s) in writing when the trial related records 
are no longer needed. ( ICH E6 (R2) ). 
The principles of record retention will also be applied to the storage of laboratory samples, 
provided that the integrity of the stored sample p ermits testing. These laboratory samples will be 
securely stored for future testing at a global Seqirus or Seqirus controlled/contracted facility for up 
to [ADDRESS_453467] access to these samples. 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 93 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453468] the his/her  samples stored for future 
testing after the study is completed, this can be indicated on the ICF.  
[ADDRESS_453469] editorial, ethical practices and current guideline s of Good Publication 
Practice (Battisti et al. 2015 ), Seqirus  will generally support publication of multicenter studies only 
in their entirety and not as individual center data. In this case, a coordinating investigator [INVESTIGATOR_363941]. The coordinating investigator [INVESTIGATOR_363942] ( CPMP/EWP/2747/00 ). 
Authorship will be determined by [CONTACT_364028]. Any formal publication of the study in which 
contribution of Seqirus  personnel exceeded that of conventional monitoring will be c onsidered as a 
joint publication by [CONTACT_364029].  
Seqirus  must be notified of any intent to publish data collected from the study and prior approval 
from Seqirus  must be obtained prior to submission for publication . 
13 ETHICAL CONSIDERATIO NS 
13.1 Regulatory and Ethical Compliance  
The study  will be conducted in compliance with the protocol, GCP , and applicable regulatory 
requirement(s) . 
This clinical study was designed and shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice  (ICH E6(R2) , with applicable 
local regulations European Direct ive 2001/20/EC, US Code of Federal Regulations Title 21 , and  
Japanese Ministry of Health, Labor, and Welfare , Seqirus  codes on protection of human rights, and 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 94 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
with the ethical principles laid down in the Declaration of H elsinki ( European Council 2001, US 
Code of Federal Regulations, ICH 1997 ). 
13.[ADDRESS_453470] the informed consent and any other materials that will be provided to the 
subjects reviewed and approved by [CONTACT_1201]/EC. This review and approval will be documented and 
stored with other study documents. The investigator or designee must fully inform the subject of all 
pertinent aspects of the study. A copy of the written informed consent will be given to the subject. 
The subject  must be allowed ample time to ask about the details of the study and to make a decision 
as to whether or not to participate in the study. The subject must  sign the consent form indicating 
their agreement to participate in the study before any study -relate d procedures are conducted. The 
informed consent process may be conducted up to [ADDRESS_453471] be agreed to by [CONTACT_364030]/EC  and a copy of the approved version 
must be provided to the Seqirus  monitor after IRB/EC  approval .  
Women of childbearing potential should be i nformed that taking the study medication may involve 
unknown risks to the fetus if pregnancy were to occur during the study and agree that in order to 
participate in the study they must adhere to the contraception requirements indicated in the protocol 
for the duration of the study. If case of doubts on the ability of a subject to adhere to these 
requirements, that subject should not be allowed in the study . 
13.3 Responsibilities of the Investigator and IRB/EC  
The protocol and the proposed informed consent form must be reviewed and approved by a 
properly constituted IRB/EC before study start. Properly constituted IRB/EC is defined in the 
integrated addendum to ICH E6: ICH Guideline for Good Clinical Practice E6  (R2). A signed and 
dated statement that the protocol and informed consent have been approved  by [CONTACT_1201]/EC  must be 
given to Seqirus  before study initiation. Prior to study start  and at any time the protocol is amended 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 95 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453472] , the investigator is required to sign a pr otocol signature [CONTACT_16066]/her agreement to conduct the study in accordance with these documents and all of the 
instructions and procedures found in this protocol and to give access to all relevant data and records 
to Seqirus  monitors, auditors, Seqirus Clinical Quality Assurance representatives, designated agents 
of Seqirus , IRBs/ ECs, and regulatory authorities as required. If an inspection of the clinical site is 
requested by a regulatory authority, the investigator must inform Seqirus  immediate ly that this 
request has been made.  
The investigator also responsible for the following:  
• Maintaining a list of appropriately qualified persons to whom the investigator has delegated 
significant study -related duties.  
• Demonstrating the capability of recruiting the required number of suitable subjects within the 
recruitment period.  
• Demonstrating sufficient time and staffing to properly conduct and complete the study within 
the agreed study period.  
• Ensuring that all persons assisting with the study are adequately informed about the protocol, 
the investigational product(s), and their study -related duties and functions  
• Ensuring that appropriately trained healthcare professionals are responsible for all study -related 
medical decisions and for ensuring appro priate medical care of subjects experiencing any AE 
related to the study.  
• If permission to do so is given by [CONTACT_423], ensuring that the subject’s primary healthcare 
provider is informed of the subject’s participation in the study.  
The investigator shou ld not implement any deviation from, or changes of the protocol without 
agreement by [CONTACT_179664]/favorable opi[INVESTIGATOR_120973]/EC of an amendment, except where necessary to eliminate an immediate hazard(s) to study  
subjects, or when the change(s) involves only logistical or administrative aspects of the study (e.g., 
change in monitor(s), change of telephone number(s)). In addition, the investigator, or person 
designated by [CONTACT_093], should document and expla in any deviation from the approved 
protocol.  
The investigator may implement a deviation from, or a change of, the protocol to eliminate an 
immediate hazard(s) to study subjects without prior IRB/IEC approval/ favorable  opi[INVESTIGATOR_1649]. As soon 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 96 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453473] emented deviation or change, the reasons for it, and, if appropriate, the 
proposed protocol amendment(s) should be submitted:  
(a) to the IRB/EC for review and approval/ favorable  opi[INVESTIGATOR_1649],  
(b) to the Sponsor for agreement and, if required,  
(c) to the regulat ory authority(ies).  
13.4 Protocol Amendments  
An amendment is a written description of change(s) to or formal clarification of a study protocol 
which may impact on the conduct of the clinical study, potential benefit of the clinical study, or 
may affect subject safety, including changes of study objectives, study design, subject population, 
sample sizes, study procedures, or significant administrative aspects. An administrative change of a 
study protocol is a minor correction or clarification that has no signific ant impact on the way the 
clinical study is to be conducted and no effect on subject safety (e.g., change of telephone 
number(s), logistical changes). Protocol amendments must be approved by [CONTACT_29322] , health 
authorities where required, and the IRB/EC . In ca ses when the amendment is required in order to 
protect the subject safety, the amendment can be implemented prior to IRB/EC  approval. 
Notwithstanding , the need for formal approval of a protocol amendment, the investigator is 
expected to take any immediate action required for the safety of any subject included in this study, 
even if this action represents a deviation from the protocol. In such cases, Seqirus  should be 
notified of this action , the IRB/EC  at the study site , and, if required by [CONTACT_1295] s, the 
relevant health authority) should be informed within [ADDRESS_453474]  
Aiello A, Farzaneh F, Candore G, Caruso C, et al. Immunosenescence and its hallmarks: how to 
oppose aging strategically? A review of potential options for therapeutic intervention. Front 
Immunol . 2019;10 :2247 . 
Baldo  V, Baldovin T, Floreani A, Carraro AM  et al. MF59 -adjuvanted influenza vaccine confers 
superior immunogenicity in adult subjects (18 -60 years of age) with chronic diseases who are at 
risk of post -influenza complications. Vaccine. 20 07;25:3955 -3961.  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 97 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
Battisti WP, Wager E, Baltzer L, Bridges D, et al. Good Publication Practice for communicating 
company -sponsored medical research: GPP3. Ann Intern Med. 2015 Sep;163:461 -464. 
Beran J, Reynales H, Poder A , et al. Prevention of influenza during mismatched seasons in older 
adults with an MF59 -adjuvanted quadrivalent influenza vaccine: a randomized, controlled, 
multicenter, phase [ADDRESS_453475] Dis. 202 1 https://doi.org/10.1016/S1473 -
3099(20)[ADDRESS_453476] seasons estimated 
influenza disease burden. Available from:  https://www.cdc.gov/flu/about/burden/2018 -2019.html  
Centers for Disease Control and Prevention, 2019. Make a strong flu vaccine recommendation; 
Information for Health Care Professionals. Ava ilable from:  
https://www.cdc.gov/flu/pdf/professionals/vaccination/flu -vaccine -rec-50-64_2019.pdf  
Clopper  CJ, Pearson ES. The use of confidence or fiducial  limits illustrated in the case of the 
binomial . Biometrika . 1934;26(4) :404-413. 
Code of Federal Regulations, 1997: Food and Drug Administration, U.S. Department of  Health and 
Human Services: Title 21, Part 11: Electronic Records Electronic Signatures.  Federal Register 
62:[ZIP_CODE].  
Committee for Medicinal Products for Human Use. Note for guidance on coordinating  investigator 
[INVESTIGATOR_363943] (CPMP/EWP/2747/00).  
European Parliament, 2001. Directive 2001/20/EC of the European Parliament and of  the Council 
of 4 April 2001. Official Journal of the European Communities. L 121/34 -44. 
Domnich A, Arata L, Amicizia D, Puig -Barberà J , et al . Effectiveness of  MF59 -adjuvanted seasonal 
influenza vaccine in the elderly : a systematic review and meta -analysis.  Vaccine . 2017;35:[ADDRESS_453477] and alternate B strain MF59 -adjuvanted trivalent influenza 
vacci nes in older adults. Vaccine. 2020 Jan 10;38(2):242 -250. 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 98 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
Fiore AE, Bridges CB, Cox NJ. Seasonal influenza vaccines. Curr Top Microbiol Immunol.  
2009;333:43 -82. 
Frey SE, Aplasca -De Los Reyes MR, Reynales H, Bermal NN , et al. Comparison of the safety and 
immunogenicity of an MF59® -adjuvanted with a  non-adjuvanted seasonal influenza vaccine in 
elderly subjects. Vaccine . 2014 ;32(39):[ADDRESS_453478] Dis. 2004;189:450 -458. 
ICH E6 (R2). (2016) ICH Harmonised Tripartite ICH Guideline for Good Clinical Practices E6  
(R2), EMA/CHMP/ICH/135/19 95. 
ICH (1998) ICH Harmonised Tripartite ICH Guideline for Statistical Principles for Clinical Trials  
E9. Federal Register, 63 (179): [ZIP_CODE]  
Lang P -O, Mendes A, Socquet J, Assir N, et al. Effectiveness of influenza vaccine in aging and 
older adults: compreh ensive analysis of the eviden ce. Clin Interv Aging 2012 ;7:55-64. 
McNeil  M. Vaccine -associated anaphylaxis. Curr Treat Options Allergy. 2019;6:297 -308. 
Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med . 1985;4:213 -226. 
Minutello M, Senato re F, Cecchinelli G, et al. Safety and immunogenicity of an inactivated subunit 
influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for 
three consecutive influenza seasons. Vaccine . 1999;17(2):99 -104. 
National Health  Services  [LOCATION_006], 2020.  
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/a ttachment_data/file/9
[ZIP_CODE]/Letter_annu alflu_2020_to_2021_update.pdf  
Noh JY , Song JY , Choi WS, Lee  J, et al. Immunoge nicity of trivalent influenza v accines in patients 
with chronic kidney disease undergoing hemodialysis: MF -59-adjuvanted versus non-adjuvanted 
vaccines . Hum Vaccin Immun other. 2016;12(11):2902 -2908 . 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 99 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
O’Hagan  D, Tsai T, Reed S. Emulsion -Based Adjuvants for Improved Influenza Vaccines . Book 
chapter : Influenza Vaccines  for the Future. 2011: 327-357. 
Pebody RG, Whitaker H, Ellis J, Andre ws N, et al. End of season influenza vaccine effectiveness in 
primary  care in adults and children in the [LOCATION_008] in 2018/19. Vaccine. 2020;38:489 -497. 
Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am J Med.  
2008;121(4):[ADDRESS_453479] . 2011; 121(8):3109 -3119.  
Temte JL, Prunusk e JP. Seasonal influenza in primary care settings: review for primary care  
physicians. WMJ. 2010;109(4):193 -200. 
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 100 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
APPENDIX 1 – PREDICTION RULE  
Prediction rule for estimating the probability of hospi[INVESTIGATOR_363944] ( Hak et al . 2004 ). 
Characteristic  Scorea 
Age, years  
<70 0 
70-74 14 
75-79 28 
80-89 42 
≥90 56 
Sex 
Female  0 
Male  9 
Outpatient visits during the previous year  
0 0 
1-6 11 
7-12 22 
>[ADDRESS_453480] total score  
Notes:  
a. The prognostic score for a given subject can be obtained by [CONTACT_364031].  
b. Pre-existing medical conditions of eligible subjects will be scored following a 
judgment by [CONTACT_093].  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 101 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
APPENDIX 2 – LIST OF ADVERSE EVENTS OF SPECIAL INTEREST  
Gastrointestinal disorders  
• Celiac disease  
• Crohn’s disease  
• Ulcerative colitis  
• Ulcerative proctitis  
 
Liver disorders  
• Autoimmune cholangitis  
• Autoimmune hepatitis  
• Primary biliary cirrhosis  
• Primary sclerosing cholangitis  
 
Metabolic diseases  
• Addison ’s disease  
• Autoimmune thyroiditis (including Hashimoto thyroiditis)  
• Diabetes mellitus type I  
• Grave's or Basedow ’s disease  
 
Musculoskeletal disorders  
• Antisynthetase syndrome  
• Dermatomyositis  
• Juvenile chronic arthritis (including Still ’s disease)  
• Mixed connective tissue disorder  
• Polymyalgia rheumatic  
• Polymyositis  
• Psoriatic arthropathy  
• Relapsing polychondritis  
• Rheumatoid arthritis  
• Scleroderma, including diffuse systemic form and CREST syndrome  
• Spondyloarthritis, including ankylosing spondylitis, reactive arthritis (Reiter's Syndrome) and 
undifferentiated spondyloar thritis  
• Systemic lupus erythematosus  
• Systemic sclerosis  
 
Neuroinflammatory disorders  
• Acute disseminated encephalomyelitis, including site -specific variants (e.g., non -infectious 
encephalitis, encephalomyelitis, myelitis, radiculomyelitis)  
• Cranial nerve disorders, including paralyses/paresis (e.g., Bell ’s palsy)  
• Guillain -Barré syndrome, including Miller Fisher syndrome and other variants  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 102 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
• Immune -mediated peripheral neuropathies and plexopathies, including chronic inflammatory 
demyelinating polyneuropathy, multifocal motor neuropathy and polyneuropathies associated 
with monoclonal gammopathy  
• Multiple sclerosis  
• Narcolepsy  
• Optic neuritis  
• Transverse myelitis  
• Myasthenia gravis, including Eaton -Lambert syndrome  
 
Skin disorders  
• Alopecia areata  
• Autoimmune bullous s kin diseases, including pemphigus, pemphigoid and dermatitis 
herpetiformis  
• Cutaneous lupus erythematosus  
• Erythema nodosum  
• Morphoea  
• Lichen planus  
• Psoriasis  
• Sweet ’s syndrome  
• Vitiligo  
 
Vasculitides  
• Large vessels vasculitis including: giant cell arteritis such  as Takayasu's arteritis and temporal 
arteritis  
• Medium sized and/or small vessels vasculitis including: polyarteritis nodosa, Kawasaki's 
disease, microscopic polyangiitis, Wegener's granulomatosis, Churg –Strauss syndrome (allergic 
granulomatous angiitis), Buerger ’s disease thromboangiitis obliterans, necrotizing vasculitis 
and anti -neutrophil cytoplasmic antibody (ANCA) positive vasculitis (type unspecified), 
Henoch - Schonlein purpura, Behcet's syndrome, leukocytoclastic vasculitis  
 
Others  
• Antiphospholipid syndrome  
• Autoimmune hemolytic anemia  
• Autoimmune glomerulonephritis (including IgA nephropathy, glomerulonephritis rapi[INVESTIGATOR_90974], membranous glomerulonephritis, membranoproliferative glomerulonephritis, and 
mesangioproliferative glomerulonephritis)  
• Autoimmune myocarditis/cardiomyopathy  
• Autoimmune thrombocytopenia  
• Goodpasture syndrome  
• Idiopathic pulmonary fibrosis  
• Pernicious anemia  
• Raynaud ’s phenomenon  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 103 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:00                                     
• Sarcoidosis  
• Sjögren ’s syndrome  
• Stevens -Johnson syndrome  
• Uveitis  
 
Protocol Number : V118_23  
Product Name:  [CONTACT_364033]: Final Version 3.0, Document Date: 11 Jul 2022  
 
Document #: FORM1 -000107830, Ed: 1.0  
Source Document #: SOP-000056619  Page 105 of 105 
Effective Date: See System Metadata         Confidential   Print Date (Local): 11-Jul-2022 15:04:[ADDRESS_453481] read the protocol entitled “A Phase 3, Randomized, Observ er-blind, Controlled, 
Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of an MF59 -adjuvanted 
Quadrivalent Subunit Inactivated Influenza Vaccine in Comparison with a Licensed 
Quadrivalent Influenza Vaccine, in Adults 50 to 64 Years of Age ”, I agree to conduct the clinical 
study, after approval by [CONTACT_180473] (as 
appropriate), in accordance with the protocol, the principles of the Declaration of Helsinki, the 
standards of Good Clinical Practic e (as defined by [CONTACT_5787]) 
and applicable regulatory requirements.  
Changes to the protocol will only be implemented after written approval is received from the 
sponsor (Seqirus) and the Institutional Review Board or Ind ependent Ethics Committee (as 
appropriate ), with the exception of medical emergencies.  
I will ensure that study staff fully understand and follow the protocol.  
 
Signature:  ……………………... ………………………  Date:  …………………………  
         (DD MMM YYYY)  
Affiliation  and qualif ications:  …………………………………………………………………  
Address of Investigator : …………………………………………………………………  
Study Protocol V118_23
Amendment 1
Amendment Issue Date: 18Nov 2021
Document #: FORM1 -000107832, Ed: 1.0
Source Document #: SOP -000056619 Page 1of 7Effective Date: See System Metadata        Confidential Print Date (Local): 19-Nov-2021 21:38:00                                  STUDY PROTOCOL V118_23
Amendment Number 1
Amendment Date: 18NOV 2021
A Phase 3, Randomized, Observer -blind, Controlled, Multicenter, Clinical Study to 
Evaluate Immunogenicity and Safety of an MF59- adjuvanted Quadrivalent Subunit 
Inactivated Influenza Va ccine in Comparison with a Licensed Quadrivalent 
Influenza Vaccine, in Adults 50 to 64 Years of Age
The present amendment introduces changes to the study protocol since the 
version 1, dated 15 April 2021 of the protocol. These changes are reflected into the 
revised protocol associated to this amendment.
Property of Seqirus **
Confidential
May not be used, divulged, published or otherwise disclosed without written
consent of Seqirus .
**“Seqirus” includes all legal entities under which the company ope rates
Study Protocol V118_23
Amendment 1
Amendment Issue Date: 18Nov 2021
Document #: FORM1 -000107832, Ed: 1.0
Source Document #: SOP -000056619 Page 2of 7Effective Date: See System Metadata        Confidential Print Date (Local): 19-Nov-2021 21:38:00                                  RATIONALE AND DESCRIPTION OF CHANGE(S)
This Amendment includes a change to address a request from CBER, as well as some 
further corrections to the statist ical definit ion of success criteria. Furthermore, updates
have been made in several  secti ons to clarify the protocol language and/or to better reflect 
current status.
Rationale for m ajor changes: 
1. The Confidence Interval (CI) forthesecondary  objective 2a (To demonstrate that 
aQIV induces a superior immune response compared w ith QIV in subjects 50- [ADDRESS_453482] one vaccine strain at 3 w eeks after vaccination ) 
hasbeen updated to reflect correct alpha .
Changes:
Section(s) Previous text: Amended text:
Synopsis, 
Secti on 2.2.1,
Secti on 
[IP_ADDRESS] , 
Secti on 
[IP_ADDRESS].1Success criteria: 
Superi or immune response will be 
demonstrated if the UL of the 95% 
CI for the inter -group GMT ratio 
(QIV/aQIV) i s <0.67 for one or 
more vaccine strains.Success criteria: 
Superi or immune response will be 
demonstrated if the UL of the 
98.73 % CI for the inter -group 
GMT ratio (QIV/aQIV) is <0.67 
for one or m ore vaccine strains.
Secti on 
[IP_ADDRESS].3No m ultiplicity adjustm ent to the 
CI levels will be implemented.No m ultiplicity adjustm ent to the 
CI levels will be implemented for 
the primary  obje ctives. For the 
secondary  endpoints, al pha was 
adjusted to 0.[ADDRESS_453483] ive 2a and 
2b so that the overall t ype I error is 
less than 0.05. The statistical 
hypotheses will be testing 
sequent ially according to the order 
of the obj ectives. Details of the 
hypothesis testing procedure will 
be specified in the SAP.
2. The Confidence Interval (CI) for the secondary  objective 2b (To demonstrate 
greater persistence of the immune response for at least one vaccine strain at 6 and 9 
mont hs after vaccination w ith aQIV compared with QIV as measured by [CONTACT_363958] 
50-64 years of age ) hasbeen updated to reflect correct alpha .
Study Protocol V118_23
Amendment 1
Amendment Issue Date: 18Nov 2021
Document #: FORM1 -000107832, Ed: 1.0
Source Document #: SOP -000056619 Page 3of 7Effective Date: See System Metadata        Confidential Print Date (Local): 19-Nov-2021 21:38:00                                  Changes:
Section(s) Previous text: Amended text:
Synopsis, 
Secti on 2.2.1,
Secti on 
[IP_ADDRESS], 
Secti on 
[IP_ADDRESS].1Succ ess criteria: 
Greater persistence o f the immune 
response will be demonstrated if 
the UL of the 95% CI for inter-
group GMT ratio (QIV/aQIV) <1.0 
for one or m ore vaccine strains.Success criteria: 
Greater persistence o f the immune 
response will be demonstr ated if 
the UL of the 98.73% CI for inter -
group GMT ratio (QIV/aQIV) <1.0 
for one or m ore vaccine strains.
Secti on 
[IP_ADDRESS].3No m ultiplicity adjustm ent to the 
CI levels will be implemented.No m ultiplicity adjustm ent to the 
CI levels will be implemented f or 
the primary  objectives. For the 
secondary  endpoints, al pha was 
adjusted to 0.[ADDRESS_453484] been 
completed .
Changes:
Section Previous text: Amended text:
Secti on 3.[ADDRESS_453485] been 
assessed .
Study Protocol V118_23
Amendment 1
Amendment Issue Date: 18Nov 2021
Document #: FORM1 -000107832, Ed: 1.0
Source Document #: SOP -000056619 Page 4of 7Effective Date: See System Metadata        Confidential Print Date (Local): 19-Nov-2021 21:38:[ADDRESS_453486] been implemented consequent to 
Estoni an EC response and questions raised during study  initiation phase
Changes:
Secti on(s) Previous text: Amended text:
Secti on 4.27.Abnorm al function of th e 
immune system result ing from:
a.Clinical condit ions;
b.Systemic administrati on of  
corticosteroi ds (PO/IV/IM)1
at a dose ≥20mg/day o f 
prednisone for more than 14 
consecut ive days within 90 
days pri or to inform ed 
consent. T opi[INVESTIGATOR_2855], inhaled 
and intranasal 
corticosteroi ds are 
permitted. Intermittent use 
(one dose in 30 days) of 
intra-articular 
corticosteroi ds is also 7.Abnorm al function of the 
immune system result ing from:
a.Clinical condit ions;
b.Systemic administrati on of  
corticosteroi ds (PO/IV/IM)1
at a dose equivalent to 
≥20mg/day of prednisone for 
more than 14 consecut ive 
days wi thin 90 days prior to 
inform ed consent. T opi[INVESTIGATOR_2855], 
inhaled and intranasal 
corticosteroi ds are permitted. 
Intermittent use (one dose in 
30 day s) of intra -articular 
corticosteroi ds is also 
permitted;
                                               
1PO= by [CONTACT_1966]; IV=intravenous; IM= intramuscular
Study Protocol V118_23
Amendment 1
Amendment Issue Date: 18Nov 2021
Document #: FORM1 -000107832, Ed: 1.0
Source Document #: SOP -000056619 Page 5of 7Effective Date: See System Metadata        Confidential Print Date (Local): 19-Nov-2021 21:38:00                                  permitted;
c.Administrati on of  
antineoplastic and 
immuno modulating agents 
or radi otherapy  within 90 
days pri or to inform ed 
consent;c.Administrati on of  
antineoplastic and 
immuno modulating agents 
or radi otherapy  within 90 
days pri or to inform ed 
consent;
9.Received an investigational or 
non-registered m edicinal 
product within [ADDRESS_453487] of this study  (note: 
concomitant participat ion in an 
observat ional study  not 
involving drugs, vaccines, or 
medical devices, is 
acceptable);9.Received an investigational or 
non-registe red m edicinal 
product within [ADDRESS_453488] of this study  (notes: i . 
concomitant participat ion in a 
study  not invo lving or no 
longer i nvolving 
administration of drugs, 
vaccines, or medical devices, is 
acceptable (e.g. studies in 
safet y follow-up phase, 
observat ional studi es); ii . 
concomitant participat ion in a 
COVID -19 vaccine study  is 
acceptable provided that the 
vaccine dosing interval
ment ioned in Exclusio n 
Criterion #1 1 is adhered to);
Study Protocol V118_23
Amendment 1
Amendment Issue Date: 18Nov 2021
Document #: FORM1 -000107832, Ed: 1.0
Source Document #: SOP -000056619 Page 6of 7Effective Date: See System Metadata        Confidential Print Date (Local): 19-Nov-2021 21:38:00                                  5. Clarificat ions on reporting requirements for solicited AEs that start during day 1 -7 
and cont inue beyond Day 14
Secti on(s) Previous text: Amended text:
Secti on 5.3 
Secti on 7.1.1, 
Secti on 
[IP_ADDRESS].2Ifasolicited local or sy stemic AE
continues beyo nd day  [ADDRESS_453489] eDi arywill be cont inued 
until the event(s) resolved or for a 
maximum o f [ADDRESS_453490] eDi arywill be cont inued 
until the event(s) resolved or for a 
maximum o f 14 day s after 
vaccination. If the reacti on 
continues to be present after Day 
14, the event and fo llow-up is to 
be captured as an unsol icited AE in 
the eCRF .
6. Correcti on how Full Analysis Set will be analyzed in case o f vaccination errors, 
consequent to CBER advice .
Changes:
Secti on(s) Previous text: Amended text:
Secti on 8.3.4 In case of vaccinat ion error, 
subjects in the FAS sets will be 
analyzed “as treated” (i.e., 
according to the vaccine the 
subject actually received, rather 
than the vaccine the subject may 
have been randomized).In case of vaccinat ion error, 
subjects in the FAS sets will be 
analyzed “as rando mized” (i.e., 
according to the vaccine the 
subject was designated to receive, 
which may  be different from  the 
vaccine the subject actually 
received).
7. Update on the analysis model for the HI GMT to include relevant covariates.
Changes:
Secti on(s) Previous text: Amended text:
Section The analysis model for the HI The analysis model for the HI 
Study Protocol V118_23
Amendment 1
Amendment Issue Date: 18Nov 2021
Document #: FORM1 -000107832, Ed: 1.0
Source Document #: SOP -000056619 Page 7of 7Effective Date: See System Metadata        Confidential Print Date (Local): 19-Nov-2021 21:38:00                                  [IP_ADDRESS].3 GMT will use a general linear 
model on log-transform ed (base 
10) Day  22 ti ters as the outcom e 
variable and as covariates: 
treatm ent groups (aQIV, and QIV), 
prevaccinat ion titer (log 10
transformed), age stratum , gender. 
From  this m odel, adjusted 
differences in the least square 
means (on the log 10scale) will be 
produced wi th 95% confidence 
limits for aQIV versus QIV. The 
estimated difference and the 
confidence limit s will be back -
transformed to obtain adjusted 
GMT ratios with 95% confidence 
limits. The adjusted GMT ratio 
will be the result for which the 
assessment of the HI GMT 
primary  endpoint will be based on. 
Each of the 4 strains will be 
analyzed separately .
Potenti al covari ate interacti on 
effects will also be examined in 
the fit of the GLM, as well as the 
other co -variates such as previous 
vaccination history  and age were 
taken as a continuous factor.GMT will use a general linear 
model on log-transform ed (base 
10) Day  22 titers as the outcome 
variable and as covariates: 
treatm ent groups (aQIV, and QIV), 
prevaccinat ion titer (log 10
transformed), age stratum, gender , 
and history  of any influenza 
vaccination wit hin the [ADDRESS_453491] square 
means (on the log10 scale) will be 
produced wi th 95% confidence 
limits for QIV versus aQIV. The 
estimated difference and the 
confidence limit s will be back -
transformed to obtain adjusted 
GMT ratios with 95% confidence 
limits. The adjusted GMT ratio 
will be the result for which the 
assessment of the HI GMT 
primary  endpoint will be based on. 
Each of the 4 strains will be 
analyzed separately .
Potenti al covari ate interacti on 
effects will also be examined in 
the fit of the GLM, as well as the 
other co-variates such as age taken 
as a continuous factor.
Summary  of minor changes: 
Clarificat ion of age range boundaries, details on number of subjects who can provide 
extra blood samples, typographical errors , minor edits and textual clarifications have been 
implemented throughout.
Study Protocol V118_23
Amendment 2
Amendment Issue Date: 11 Jul 2022
Document #: FORM1 -000107832, Ed: 1.0
Source Document #: SOP -000056619 Page 1of 7Effective Date: See System Metadata        Confidential Print Date (Local): 11-Jul-2022 21:12:00                                  STUDY PROTOCOL V118_23
Amendment Number 2
Amendment Date: 11 JUL 2022
A Phase 3, Randomized, Observer -blind, Controlled, Multicenter, Clinical Study to 
Evaluate Immunogenicity and Safety of an MF59- adjuvanted Quadrivalent Subunit 
Inactivated Influenza Vac cine in Comparison with a Licensed Quadrivalent 
Influenza Vaccine, in Adults 50 to 64 Years of Age
The present amendment introduces changes to the study protocol since the 
version 2, dated 18 Nov 2021 of the protocol. These changes are reflected into the
revised protocol associated to this amendment.
Property of Seqirus **
Confidential
May not be used, divulged, published or otherwise disclosed without written
consent of Seqirus .
**“Seqirus” includes all legal entities under which the company operat es
Study Protocol V118_23
Amendment 2
Amendment Issue Date: 11 Jul 2022
Document #: FORM1 -000107832, Ed: 1.0
Source Document #: SOP -000056619 Page 2of 7Effective Date: See System Metadata        Confidential Print Date (Local): 11-Jul-2022 21:12:00                                  RATIONALE AND DESCRIPTION OF CHANGE(S)
This Amendment includes a reclassificati on of one of the secondary objectives regarding 
9 months persistence to become an exploratory objective , acorrecti on of  an inconsistency 
in the analysis of local so licited reacti onsand an improvement in the definit ion of 
previous influenza vaccinat ion. 
Rationale for m ajor changes: 
To expedite theprimary and secondary immunogenicit y resul ts and to report them wit h 
the com plete safet y data to support timely license applica tions in different regions, the 
analyses o f immunogenicit y persistence at [ADDRESS_453492] on the serum  antibody  testing 
strategy  will be that the 9 m onth sample s will be assayed at a later time, and that those 
later runs of the 9 month sera will include repeat assay s of the baseline sera (Day  1) in the 
same testing. These repeat Day  1 resul ts will beused only  for the Day  271 stati stical 
analyses (e.g. seroconversio n rates, m odeling covari ates, etc.), as described in the SAP. 
Changes:
Secti on(s) Previous text: Amended text:
Synopsis, 
Secti on 2.2.1 , 
Secti on
[IP_ADDRESS].1To dem onstrate greater persistenc e 
of the immune response for at least 
one vaccine strain at [ADDRESS_453493] ive:
- To further evaluate the 
immunogenicit y of aQIV 
compared wi th QIV in subjects 
50-[ADDRESS_453494] ives
:
-To evaluate persi stence of the 
immune response at 9 months 
after vaccination wit h aQIV 
compared wi th QIV as measured 
by [CONTACT_363958] 50 -64 years of 
age.
-To further evaluate the 
Study Protocol V118_23
Amendment 2
Amendment Issue Date: 11 Jul 2022
Document #: FORM1 -000107832, Ed: 1.0
Source Document #: SOP -000056619 Page 3of 7Effective Date: See System Metadata        Confidential Print Date (Local): 11-Jul-2022 21:12:[ADDRESS_453495] with study 
centers, will remain blinded to the 
treatm ent codes until the clinical 
database has been locked ,protocol  
deviat ions (except for Day  271 
serum  sample analysis PDs) have 
been assessed ,and the data have 
been released fo r statistical 
analysis .The analysis on the 
primary  and secondary object ives 
for the final CSR will be 
conducted on this data.
All personnel invo lved in 
processing samples and 
performing laboratory  assays will 
remain blinded to the treatment 
codes until al l Day [ADDRESS_453496] ive will 
be conducted on this data and 
reported in a CSR addendum.
Further details are specified in a 
study  specific Blind ing 
Maintenance Plan.
Secti on 3.10 Evaluat ion of the primary and 
secondary  immunogenici ty 
objectives requires the testing of 
biological  samples from  the study  
subjects, which can only be 
completed after all samples are Evaluat ion of the primary and 
secondary  immunogenici ty 
objectives requires the testing of 
biological  samples from  the study  
subjects, which can only be 
completed after all of thesamples 
Study Protocol V118_23
Amendment 2
Amendment Issue Date: 11 Jul 2022
Document #: FORM1 -000107832, Ed: 1.0
Source Document #: SOP -000056619 Page 4of 7Effective Date: See System Metadata        Confidential Print Date (Local): 11-Jul-2022 21:12:[ADDRESS_453497] samples for the 
analysis of the secondary 
objectives will be taken at Visit 6 
(Day  271). For the purpose of this 
protocol , end of study  is defined as 
the com pletion of  the testing of 
such bio logical samples, to be 
achieved no later than [ADDRESS_453498] 
biological  sample at 6 (Day  271).for these obj ectives are collect ed. 
The l ast sam ples for the analysis of 
the secondary  object ives will be 
taken at Visit 5 (Day  181). The l ast 
clinical assessment for the 
secondary  safety  objective will be 
at Vi sit 6 (Day  271). Accordingly , 
for the purpose of this protocol, 
end of study  is defined as the 
completion of the testing o f the 
Visit 5 (Day  181) bi ological  
samples, to be achieved no later 
than [ADDRESS_453499] biological sample at Vi sit 5 
(Day  181) or the Last Subject Last 
Visit, whichever i s late r. The local
end of the study  is defined as the 
Last Subject Last Visit within the 
country .
Secti on 7.3 (No prior statement )
For the exploratory
immunogenicit y object ive, 
immune responses maybe 
evaluated with addi tional assays, 
such as testing agains t 
heterol ogous strains or alternat ive For the exploratory  objective of 
persistence of the immune 
response at 9 months after 
vaccination, HI ant ibody  responses 
for all strains included in the study  
vaccines will be evaluated using an 
egg-derived target virus at a later 
stage .For this analysis, Day 1 
serum  samples obtained forthe 
primary  and secondary study  
objectives (noninferiorit y and 
superi ority assessments) will be 
retested. Day  [ADDRESS_453500] 
Study Protocol V118_23
Amendment 2
Amendment Issue Date: 11 Jul 2022
Document #: FORM1 -000107832, Ed: 1.0
Source Document #: SOP -000056619 Page 5of 7Effective Date: See System Metadata        Confidential Print Date (Local): 11-Jul-2022 21:12:00                                  assay methods (e.g., MN) . heterol ogous strains or alternat ive 
assay methods (e.g., MN) .
Secti on 
8.1.2.32b. Greater persistence o f the 
immune response of aQIV 
compared to QIV  will be assessed 
for HI GMT for the strains 
included in the vaccines as 
follows:
•The GMT ratio (QIV/aQIV) at 
Days 181 and 271.2b. Greater persistence o f the 
immune response of aQIV 
compared to QIV  will be assessed 
for HI GMT for the strains 
included in the vaccines as 
follows:
•The GMT ratio (QIV/aQIV) at 
Day 181.
Secti on 
[IP_ADDRESS](No prior statement )
Explorato ry immunogenicit y 
endpo ints that may be assessed in 
the study  include t he measures of 
immunogenicit y of aQIV and QIV 
as determined by  [CONTACT_364032]  1, Day  
22, Day  181, and Day 271 
(depending on availab ility ofPersi stence of the immune 
response of aQIV compared to 
QIV at Day  [ADDRESS_453501] ive 2c, and 
further explored through the GMT 
ratio (QIV/aQIV). For this 
analysis, Day  [ADDRESS_453502] ives 
(noninferiorit y and superiori ty 
asses sments) will be retested. Day  
[ADDRESS_453503] ho molo gous or 
heterol ogous strains at Day  1, Day  
22, Day  181, and Day 271 
(depending on availabilit y of
Study Protocol V118_23
Amendment 2
Amendment Issue Date: 11 Jul 2022
Document #: FORM1 -000107832, Ed: 1.0
Source Document #: SOP -000056619 Page 6of 7Effective Date: See System Metadata        Confidential Print Date (Local): 11-Jul-2022 21:12:00                                  adequate sera and on assay  
availabilit y). Details will be 
described in the SAP .adequate sera and on assay  
availabilit y). Details w ill be 
described in the SAP .
Secti on 
[IP_ADDRESS] Greater persistence of the immune 
response will be demonstrated if the 
UL of the 98.73% CI for the inter-
group GMT ratio (QIV/aQIV) <1.0 
for one or more vaccine strains at 6 
months and subsequently at 9 
monthsGreater persistence of the immune 
response will be demonstrated if the 
UL of the 98.73% CI for the inter-
group GMT ratio (QIV/aQIV) <1.[ADDRESS_453504] received 
an influenza vaccinat ion within the previous 3 influenza seasons as previously vaccinated 
subjects (Yes). The original text was meant not to be lit erally 3 times 365 days prior to 
the randomization date, but the 3 prior influenza years/seasons, and was implemented as 
such. 
Changes:
Secti on(s) Previous text: Amended text:
Synopsis, 
Secti on 3.6.1, 
Secti on 6.5, 
Secti on 
[IP_ADDRESS].3Stratificat ion for histor y of any 
influenza vaccinat ion within the 
previous 3 influenza years (y es/no) 
will be applied to all subjects.Stratificat ion for history  of any 
influenza vaccinat ion within the 
previous 3 influenza seasons 
(yes/no) will be applied to all 
subjects.
To ensure consistency wit h the approved labelling informat ionfor aQIV ( Fluad 
Quadrivalent/ Quad/ Tetra ), assessment and reporting of so licited local react ions has been 
updated to consider local events as being present if measured ≥25 mm.
Changes:
Secti on(s) Previous text: Amended text:
Secti on 
[IP_ADDRESS].2Each so licited local and systemic 
AE will also be fur ther 
summarized as “none” versus 
“any”. “Any” will include 
measurements with a diameter of Each so licited local and systemic 
AE will also be further 
summarized as “Present” versus 
“Absent”. “Present” will include 
measurements with a diameter of 
Study Protocol V118_23
Amendment 2
Amendment Issue Date: 11 Jul 2022
Document #: FORM1 -000107832, Ed: 1.0
Source Document #: SOP -000056619 Page 7of 7Effective Date: See System Metadata        Confidential Print Date (Local): 11-Jul-2022 21:12:[ADDRESS_453505] 25 mm.
Summary  of minor changes: 
Typographi cal errors and minor edi ts have been implemented throughout.